



Vaccines and Global Health: The Week in Review
01 February 2025 :: Issue 784
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

:: [Think Tanks](#)

:: [Public Consultations/Call for Inputs/Call for Papers](#)

Milestones, Perspectives

.....
.....

U.S. Funding Freeze – Global Health

Editor's Note:

We have not identified official information clarifying with any precision how the U.S. funding freeze on foreign assistance impacts specific global health programs, research initiatives or organizations. *The New York Times* report below [excerpts] is the latest credible analysis we have encountered.

Health Programs Shutter Around the World After Trump Pauses Foreign Aid

Lifesaving treatment and prevention programs for tuberculosis, malaria, H.I.V. and other diseases cannot access funds to continue work.

New York Times, Feb. 1, 2025 - Updated 4:52 p.m. ET

By Stephanie Nolen

[Excerpts]

Lifesaving health initiatives and medical research projects have shut down around the world in response to the Trump administration's 90-day pause on foreign aid and stop-work orders...

Dozens of clinical trials in South Asia, Africa and Latin America have been suspended. Thousands of people enrolled in the studies have drugs, vaccines and medical devices in their bodies but no longer have access to continuing treatment or to the researchers who were supervising their care.

In interviews, more than 20 researchers and program managers described the upheaval in health systems in countries across the developing world. Most agreed to be interviewed on the condition that their names not be published, fearing that speaking to a reporter would jeopardize any possibility that their projects might be able to reopen.

Many of those interviewed broke down in tears as they described the rapid destruction of decades of work.

The programs that have frozen or folded over the past six days supported frontline care for infectious disease, providing treatments and preventive measures that help avert millions of deaths from AIDS, tuberculosis, malaria and other diseases. They also presented a compassionate, generous image of the United States in countries where China has increasingly competed for influence.

The State Department and U.S.A.I.D. did not respond to requests for comment...

...a federal judge blocked the freeze until Feb. 3. But in practice, most U.S.A.I.D. country offices and programs are proceeding as if the freeze remains in place.

They have been unable to obtain clarification on whether and when their work can continue because their assigned contacts at U.S.A.I.D. have either been fired or furloughed, or are under strict instructions to not talk to anyone.

Despite the court order, thousands of people have already lost their jobs as a result of the freeze. About 500 U.S.-based employees of U.S.A.I.D. were fired. In countries from India to Zimbabwe, staff

members for health projects were immediately fired. An organization called the International Centre for Diarrhoeal Disease Research, Bangladesh, which does research on a top killer of children, laid off more than 1,000 employees this week.

If the waiver announced by Mr. Rubio does not apply to their work — as is likely because it is expected to exempt only a narrow scope of activities — many nonprofit groups will not have enough funds to pay their employees or maintain supplies. Already, organizations that rely on U.S.A.I.D. funds have not been able access any money, even for reimbursement of expenses already incurred...

U.S.A.I.D.'s largest project is called the global health supply chain, an effort to streamline procurement of supplies for H.I.V., malaria, maternal health and other key areas, to make the system more efficient and save money. It operates in more than 55 countries where, in many cases, it supplies the bulk of key medicines. Now its global web of staff has been ordered to stop work except for essential tasks, like guarding commodities in warehouses...

.....
.....

U.S. Foreign Assistance – Emergency Humanitarian Waiver

Emergency Humanitarian Waiver to Foreign Assistance Pause

The Secretary of State

January 28, 2025

To: All implementing U.S. government agencies, partners, and NGOs.

For the purposes of carrying out the President's Executive Order on Reevaluating and Realigning United States Foreign Aid, I am approving an additional waiver of the pause under the Executive Order on Reevaluating and Realigning United States Foreign Aid and my subsequent direction of January 24, 2025, **for life-saving humanitarian assistance during the period of the review.**

Implementers of existing life-saving humanitarian assistance programs should continue or resume work if they have stopped, subject to the following directions. **This resumption is temporary in nature, and except by separate waiver or as required to carry out this waiver, no new contracts shall be entered into.**

1. (a) **For purposes of this waiver, life-saving humanitarian assistance applies to core life-saving medicine, medical services, food, shelter, and subsistence assistance, as well as supplies and reasonable administrative costs as necessary to deliver such assistance.**
(b) This waiver does not apply to activities that involve abortions, family planning, conferences, administrative costs other than those covered by 1(a) above, gender or DEI ideology programs, transgender surgeries, or other non-life saving assistance.
(c) **Migration and Refugee Assistance (MRA) may only be used to support activities under section 1(a) and for repatriation of third country nationals to their country of origin or safe-third-country.**
2. Additional waivers or exceptions for humanitarian assistance not covered by this waiver may be sought through the Director of Foreign Assistance at the Department of State. Implementing partners and NGOs are to work through their U.S. government agency partners on such requests.

.....
.....

Africa – “Health and Security Crisis”

Africa CDC Urges Immediate Action to Protect Lives Amid Escalating Health and Security Crises

1 February 2025

To the attention of African Heads of State and Government

*Through H.E. Mohamed Ould Ghazouani, President of Mauritania, Chair of African Union, Chair of Africa CDC Committee of Heads of State and Government
Through H.E. Moussa Faki, AUC chairperson*

Your Excellencies,

Africa is facing an unprecedented convergence of crises that threaten to reverse decades of progress in health security and economic development. **The number of health emergencies on the continent surged from 153 outbreaks in 2022-2023 to 242 in 2024**, significantly increasing the risk of another pandemic emerging from Africa. At the same time, shifting global priorities have led many traditional partners to reduce development assistance, including the recent announcement of a 90-day pause in U.S. foreign aid.

The consequences of inaction are severe. Africa CDC projections indicate that without urgent intervention, **financial constraints could reverse our hard-won health gains, leading to an estimated 2 to 4 million additional deaths per year from preventable and treatable diseases**. This human toll translates into massive economic losses, pushing an estimated 39 million more people into poverty and costing the continent billions annually. This is not just an African crisis—it is a global crisis in the making.

Africa CDC has taken swift action to mitigate the impact of these developments. Upon learning of the **U.S. funding pause**, we immediately engaged the new administration. I took this message to global platforms, including my interview to CNN on 28 January 2025, advocating for a waiver for life-saving humanitarian assistance. As a result, a waiver was granted to ensure critical interventions continue including HIV medications. **However, this is only one battle. It is a wake-up call for Africa to take charge of its own health security by accelerating innovative financing mechanisms and increasing domestic investment in public health.**

While Africa is making efforts to protect its people, peace remains the missing element. Nowhere is this more evident than in Goma, eastern Democratic Republic of Congo (DRC). This is not only a security issue—it is a full-scale public health emergency. Goma, a city of three million people, including one million displaced individuals, has one of the highest population densities in the world—39,620 people per square kilometer—without adequate health infrastructure or access to basic services such as water, sanitation, and hygiene.

These extreme conditions, combined with insecurity and mass displacement, have fueled the mutation of the Mpox virus, generating the deadly Clade 1b variant in 2023. Goma has become the epicenter, spreading Mpox across 21 African countries, including SADC and EAC states. This strain has already claimed thousands of lives, particularly among children and young people, and has proven to be highly sexually transmissible.

These same conditions have also led to widespread measles, cholera and other outbreaks, claiming thousands more lives. Africa CDC has worked tirelessly to secure Mpox vaccines and other essential health commodities for Goma and eastern DRC. However, without peace and security, these supplies cannot reach the children and mothers who need them most.

I am prepared to personally fly to Goma and oversee the delivery of these life-saving interventions-but security is essential.

Your Excellencies, this war must end. **If decisive action is not taken, it will not be bullets alone that claim lives—it will be the unchecked spread of major outbreaks and potential pandemics that will come from this fragile region** (please let us not forget the lessons from CoVID), devastating economies and societies across our continent. Our collective survival depends on urgent action from Your Excellencies' decisions.

Your leadership is critical in this moment. Africa's future and survival depend on your ability to act swiftly, decisively, and together. Africa CDC remains committed to working with Your Excellencies to protect lives, strengthen our health systems, and ensure a safer, healthier continent for future generations.

Yours sincerely,

HE. Dr. Jean Kaseya

Director General, Africa CDC

.....
.....

IPPS – 100 Days Mission Report

The world remains unprepared for another global pandemic, despite national bright spots, as the 4th Implementation Report of the 100 Days Mission is launched in Cape Town

January 30, 2025

- Latest 100 Days Mission Implementation Report shows **the world remains unprepared for another global pandemic, five years after the COVID-19** Public Health Emergency of International Concern (PHEIC) declaration.
- The *2024 100DM Scorecard* reveals **limited progress in terms of newly approved diagnostics, therapeutics, and vaccines (DTVs)**.
- Despite the ongoing mpox PHEIC, there are still no effective point of care diagnostics or treatments for the newly identified clade.
- **H5N1 looms as a potential threat**, but clarity is needed on the efficacy of current influenza vaccines, therapeutics, and diagnostics against this emerging strain.
- Rwanda's successful response to the 2024 Marburg outbreak offers hope, demonstrating that the 100 Days Mission is achievable with strong preparation and leadership.
- Experts convene in Cape Town as South Africa begins its G20 presidency, seeking to learn from African outbreak responses and advance harmonisation between national, regional, and global approaches to health security...

New data from the 2024 Scorecard shows:

- **Limited new approvals:** Only six new diagnostic tests (for Chikungunya and Ebola) and one therapeutic (Ebola monoclonal antibody treatment) were approved, with no new vaccines for priority pathogens from Scorecard 1.0.
- **Early pipeline progress: Seven vaccines entered Phase 1 trials, but only one advanced to Phase 3.** The therapeutics pipeline saw just two candidates progress to phase 1 and 2 trials, highlighting limited development for non-COVID pathogens.
- **Declines in funding:** Non-COVID DTV funding fell by 31% from 2022 to 2023, with sharp decreases for Rift Valley Fever (92%), MERS (84%), and SARS (77%), while overall R&D funding for priority pathogens remains reactive.

- **Over-reliance on dominant funding sources:** The U.S. government accounted for 60% of global R&D funding (68% excluding COVID-19), highlighting the need for other funders to step in and share both investments and benefits...

The 100 Days Mission Implementation report highlights three key areas for action in 2025

that would ensure the world is better prepared for future outbreaks. The report calls on all stakeholders to work together to:

1. **Reinvigorate the therapeutics pipeline** with a focus on early-stage R&D: Prioritise early-stage research and development to advance therapeutics for priority viral families, ensuring robust pipelines are prepared to address emerging threats.
2. **Enhance coordination to implement the Diagnostics 100DM roadmap:** Collaborate with global partners to implement the 100 Days Mission diagnostics roadmap, improving alignment and advancing innovation across the diagnostics sector.
3. **Sustain clinical trial infrastructure and strengthen preparatory regulatory approaches:** Ensure clinical trial networks remain functional between pandemics and adopt harmonised regulatory approaches to accelerate approvals during emergencies...

Looking ahead, the IPPS calls on G7 and G20 leaders, with Canada and South Africa respectively assuming their presidencies for 2025, to catalyse global action by:

- **Accelerating diagnostic, therapeutic and vaccine R&D for priority pathogens** with equity embedded by design
- Agreeing **a shared framework for regulatory preparedness** in order to increase harmonisation and safely accelerate emergency authorisations.
- Enhancing collective health security by expanding biosafety, biosecurity and pre-clinical capabilities

With just two years left in its mandate, the IPPS remains committed to working with all partners to drive systemic change and ensure that the lessons of COVID-19 and subsequent outbreaks result in a safer, more prepared world.

International Pandemic Preparedness Secretariat

The IPPS is a wholly independent entity that serves to join up relevant states, the private sector, and global health institutions in support of the 100 Days Mission. The Secretariat works with the G7, G20, industry and the WHO as key partners. The Secretariat was recommended by G7 Scientific Advisors, but is not a formal G7 body.

.....
.....

AMR

Costing Antimicrobial Resistance Interventions

Center for Global Development *WORKING PAPERS*

Tim Laurence and Anthony McDonnell

January 29, 2025

Abstract

This study estimates the costs of four key interventions to mitigate antimicrobial resistance globally by 2050. These interventions include improving access to water, sanitation, and hygiene, enhancing childhood vaccination, developing new antibiotics, and increasing access to healthcare and existing antibiotics. Using updated and original costing methods, including a novel Cobb-Douglas production function to cost improved access to healthcare and antibiotics, the total annual costs for these interventions are estimated for 204 countries. The key findings are as follows: it would cost \$215.0 billion to scale up household WASH globally, \$4.7 billion to achieve 100 percent access to a group of

childhood vaccines, and \$2.2 billion to develop new antibiotics. Additionally, \$59.0 billion would be required to improve access to healthcare and antibiotics. Given that all countries benefit from rolling out these policies, there is a compelling case for high-income countries providing assistance to low- and middle-income countries to help them combat antimicrobial resistance.

Executive summary [excerpt]

The Institute for Health Metrics and Evaluation (IHME) has modelled several prospective scenarios of the burden of antimicrobial resistance (AMR) to 2050, including interventions seeking to mitigate AMR.

These intervention scenarios are:

1. Improving access to water, sanitation and hygiene (WASH) for households
2. Improving access to childhood vaccination
3. Developing new innovative gram-negative antibiotics
4. Improving access to healthcare and existing antibiotics

All these interventions are compared to IHME's reference scenario. This piece of work is the costing companion to those intervention scenarios, estimating approximate country costs to inform financing and resource allocation discussions. We report aggregated costs in this paper and country level estimates are available in the appendix.

WASH: We review relevant literature on the global cost of WASH and update previous estimates by UNICEF and the World Bank on the cost to scale up WASH at a country level for both cost inflation and changes of coverage modelled by IHME. We estimate that the global cost of scaling up WASH to achieve Sustainable Development Goals (SDG) 6.1 and 6.2 is £215.0 billion annually. This estimate is broadly consistent with comparable existing estimates. It is important to note that scaling up WASH has wide ranging benefits past AMR, so the considerable global cost should be viewed against the wide-ranging benefits set out by studies.

Vaccination: We review relevant literature on the global cost of vaccination. We produce novel bottom-up estimates of the cost of closing the vaccination gap at a country level globally. We use data from the MI4A database from the World Health Organization on vaccination costs, and assumptions on the delivery cost of vaccination in order to cost the changing coverage modelled by IHME. We estimate that the cost of scaling up vaccination in line with IHME's modelling is \$4.6 billion annually. Our estimates are broadly consistent with existing literature.

Innovation: Developing new antibiotics, particularly targeting gram-negative bacteria, is crucial to mitigating the growing burden of AMR. IHME's model suggests that halving the impact of resistant gram-negative infections would require ten new antibiotics developed per decade, two-thirds of which should be gram-negative focused. Using cost estimates from existing literature we calculate an initial annual cost of \$2.2 billion, which, due to rising R&D costs, is expected to increase to \$3.7 billion by 2050. We explore five potential funding models to distribute these costs equitably, with particular focus on scenarios where high-income countries bear the majority of the burden, ensuring that low-income countries are not disproportionately impacted.

Access to healthcare: We were unable to identify closely comparable studies estimating the global cost of increasing antibiotic access. IHME model this intervention by estimating the potential **3** benefits of access *if* it meant countries achieve better bacterial infection outcomes. We develop an original modelling approach, fitting a Cobb-Douglas production function to estimate how resources (antibiotics and other healthcare) are transformed into health outcomes. We use this model to estimate that the additional funding required to close the antibiotic access gap is \$59.0 billion annually. This estimate is subject to more limitations than the others because the healthcare.

.....

CGD WORKING PAPERS
[The Global Direct Inpatient Cost of Antimicrobial Resistance: A Modelling Study](#)
Tim Laurence et al.
January 29, 2025

This study estimates the global inpatient healthcare costs attributable to antimicrobial resistance (AMR) and projects future expenditures across different scenarios. It finds that AMR accounts for 25.4 million hospital admissions annually, resulting in \$66.4 billion in excess healthcare costs, with...

CGD WORKING PAPERS
[Modelling the Global Economic Impact of Antimicrobial Resistance in Humans](#)
Amanda Countryman and Anthony McDonnell
January 29, 2025

Antimicrobial resistance (AMR) poses a major global challenge, affecting both human health and economies. This research models the potential impacts of AMR on global GDP and various sectors, showing that while better treatment and combined interventions can boost economic growth, accelerated resista...

.....
.....

mPox – PHEIC

[Multi-country outbreak of mpox, External situation report #46 - 28 January 2025](#)

KEY FIGURES			
Reporting period: 1 January 2022 – 31 December 2024			
Area	Number of reported confirmed cases	Number of deaths among confirmed cases	Number of reporting countries
Global	124 753	272	128
Reporting period: 1 January 2024 – 19 January 2025			
Area	Number of reported confirmed cases	Number of deaths among confirmed cases	
Africa	20 345	64	
Democratic Republic of the Congo ¹	14 530	43	
Burundi	3116	1	
Uganda ²	2031	10	
Reporting period: last six weeks, 9 December 2024 – 19 January 2025			
Africa	2935	5	
Democratic Republic of the Congo	1316	0	
Burundi	570	0	
Uganda	984	5	

Highlights

- The outbreak of mpox due to clade Ib monkeypox virus (MPXV) continues predominantly in the Democratic Republic of the Congo, Burundi and Uganda, with new travel-related cases identified in previously unaffected countries.
- The Democratic Republic of the Congo remains the most affected country, experiencing circulation of both clade I MPXV subclades. Despite many of the provinces reporting stable trends in cases, the situation in the country remains concerning, with continued sustained circulation of virus strains. The escalating violence in the eastern part of the country poses additional challenges for the mpox response.
- Burundi and Uganda continue to report the most cases outside of the Democratic Republic of the Congo.
- New travel-related cases of mpox due to clade Ib MPXV have been detected in countries that had already detected travel-related cases before, including China, Germany, Thailand, the United Kingdom of Great Britain and Northern Ireland and the United States of America.
- Azerbaijan has reported its first case of mpox. Information on the MPXV clade is not yet available.

... 5. Access to and delivery of countermeasures

Access and Allocation Mechanism (AAM)

Vaccines

- WHO has continued to provide technical support to accelerate implementation and uptake of mpox vaccination in affected countries in at-risk groups, in support of controlling the surge in mpox cases on the African continent.
- Efforts are underway to advance delivery of remaining vaccine doses that were allocated during the first allocation round, to finalize the outstanding shipment arrangements and documentation. Nine countries have been allocated vaccine doses and six countries have fully accepted their allocation (Democratic Republic of the Congo, Rwanda, Kenya, Liberia, South Africa, and Uganda)
- To date, 465 760 vaccines have been delivered to six countries and vaccination has started in four countries (Central African Republic, Democratic Republic of the Congo, Nigeria, and Rwanda).
- Over 4.83 million vaccine doses are expected to be available in 2025. The vaccine supply includes contributions from multiple nations and organizations, including 1.73 million dose donations of MVA-BN vaccine (150 000 doses from the European Union, 696 200 doses from the United States, 876 300 doses procured through UNICEF/Gavi), 50 000 doses of ACAM2000 vaccine from Emergent BioSolutions, as well as a further 3.05 million doses of LC16m8 vaccine from Japan.
- The AAM partners have continued to work together to ensure countries receive guidance to get operational funds for implementation of the national vaccination plans.

.....
.....

Polio – PHEIC

Polio this week – 29 January 2025

Headlines

- With deep sorrow we announce the passing of our colleague, Abid Shaikh, who served as a Programme Assistant with the Polio Programme in Pakistan since 1999...
- Global health experts convene in Pakistan for emergency measures to stop endemic polio once and for all. [More](#).
- The WHO Executive Board will take place in Geneva next week (3-11 February). The GPEI has finalized a report on polio eradication, which will help inform Member State discussions. The report provides an update on work towards fully implementing and financing the Polio Eradication Strategy

and the Polio Transition Framework, to achieve eradication and prepare for a lasting polio-free world. The report is available [here](#).

Summary of new polioviruses this week, cases and positive environmental isolates:


- Pakistan: one WPV1 case and three WPV1-positive environmental samples
- Ethiopia: ten cVDPV2 cases
- Niger: one cVDPV2 case

.....

Polio transition strategic framework: Global Vision to use polio investments to build strong, resilient and equitable health systems

WHO - 27 January 2025 – Global Strategy

Fig. 2. Polio transition strategic framework: global vision.



Overview

The Global Vision to use polio investments to build strong, resilient and equitable health systems is the umbrella for the Polio transition strategic framework, which updates the Strategic Action Plan on Polio Transition (2018-2023). It builds on stakeholder feedback to set the strategic direction to sustain the polio investments – the tools, knowledge and infrastructure built to eradicate polio over the past decades – and use this legacy to keep the world polio-free and build strong, resilient and equitable health systems.

Polio transition strategic framework: Monitoring and evaluation

WHO - 27 January 2025 | Manual

Overview

The polio transition monitoring and evaluation (M&E) framework has been designed to monitor progress towards achieving the strategic and operational outcomes of the post-2023 polio transition strategic framework, as outlined in the Global vision to use polio investments to build strong, resilient and equitable health systems, and Regional Strategic Plans for the WHO African, Eastern Mediterranean and South-East Asia Regions. It aims to support an efficient and effective polio transition process through both process and outcome-based monitoring. The framework promotes accountability and strives for a harmonized approach to monitoring and evaluating polio transition at the country, regional and global level.

.....
.....

Public Consultations/Call for Inputs/Call for Papers

E6(R3) Good Clinical Practice: Annex 2; International Council for Harmonisation; Draft Guidance for Industry; Availability

A Notice by the Food and Drug Administration on 12/30/2024 **Comment period ends 02/28/2025**

SUMMARY:

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "E6(R3) Good Clinical Practice: Annex 2." The draft guidance was prepared under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The draft guidance is the second annex to "E6(R3) Good Clinical Practice" published June of 2023. This annex provides additional considerations for the application of good clinical practices to a variety of trial designs and data sources. Specifically, this draft guidance discusses trials with decentralized and pragmatic elements and real-world data sources. This draft guidance highlights the importance of quality by design and focusing efforts and resources on critical aspects of the trials that might impact the safety of participants and the reliability of results. The draft guidance is intended to encourage innovation in trial design and provides flexible, modern, and clear good clinical practices for conducting trials, while avoiding unnecessary complexities.

.....
.....

Contents [click to move among sections]

:: Milestones, Perspectives

:: WHO

:: Organization Announcements

:: Journal Watch

:: Pre-Print Servers

.....
.....

WHO & Regional Offices [to 01 Feb 2025]

<https://www.who.int/news>

Selected News/Announcements/Statements

31 January 2025 *News release*

WHO and partners enable access to candidate vaccine and treatments for outbreak of Sudan Ebola virus disease in Uganda

WHO and partners have immediately boosted their support to the Ugandan government's response to an outbreak of Sudan virus disease outbreak (SVD, part of the Ebola family), including by facilitating access to a candidate vaccine and candidate treatments. The first 2160 doses of the vaccine candidate and the treatments are already in Kampala, Uganda, as they were prepositioned as part of outbreak preparedness.

The vaccine trial processes underway include orientation of the research teams on the trial procedures, and logistics arrangements. Research teams have been deployed to the field to work along with the surveillance teams as approvals are awaited.

The candidate vaccine and the candidate treatments (a monoclonal antibody and an antiviral) are being made available through clinical trial protocols, which will make it possible to further document their efficacy and safety...

30 January 2025 *News release*

WHO verifies Niger as the first country in the African Region to eliminate onchocerciasis

29 January 2025 *News release*

Guinea eliminates human African trypanosomiasis as a public health problem

28 January 2025 *Statement*

WHO statement on potential global threat to people living with HIV

The World Health Organization (WHO) expresses deep concern about the implications of the immediate funding pause for HIV programmes in low- and middle-income countries. These programmes provide access to life-saving HIV therapy to more than 30 million people worldwide. Globally, 39.9 million people were living with HIV at the end of 2023.

A funding halt for HIV programmes can put people living with HIV at immediate increased risk of illness and death and undermine efforts to prevent transmission in communities and countries. Such measures, if prolonged, could lead to rises in new infections and deaths, reversing decades of progress and potentially taking the world back to the 1980s and 1990s when millions died of HIV every year globally, including many in the United States of America.

For the global community, this could result in significant setbacks to progress in partnerships and investments in scientific advances that have been the cornerstone of good public health programming, including innovative diagnostics, affordable medicines, and community delivery models of HIV care.

We call on the United States Government to enable additional exemptions to ensure the delivery of lifesaving HIV treatment and care...

.....

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region AFRO

:: 30 January 2025

WHO accelerates efforts to support response to Sudan virus disease outbreak in Uganda

:: 30 January 2025

Communities mobilize to end Guinea-worm disease in the Democratic Republic of the Congo

WHO Region of the Americas PAHO

:: 27 Jan 2025

[New UN Report: 74 percent of Latin American and Caribbean countries are highly exposed to extreme weather events, affecting food security](#)

Climate variability and extreme weather events (such as droughts, floods, and storms) are reducing agricultural productivity, disrupting food supply chains, increasing prices, impacting food environments, and threatening progress in reducing hunger and malnutrition in the region. 27 of January 2025, Santiago de Chile –Changing patterns of climate...

WHO South-East Asia Region SEARO

:: 30 January 2025 Statement

[World Neglected Tropical Diseases Day 2025: Unite. Act. Eliminate.](#)

WHO European Region EURO

:: 27 January 2025 News release

[Cervical cancer elimination: progress evident, but tragically slow](#)

WHO Eastern Mediterranean Region EMRO

[A tale of resilience in Lebanon: voices from the south](#)

27 January 2025

[Islamic Republic of Iran takes centre stage in global fight for rare blood access](#)

27 January 2025

[Bringing health care closer to displaced communities in Somalia](#)

26 January 2025

WHO Western Pacific Region

:: 27 January 2025

[National influenza centres are the backbone of early detection and disease outbreak response](#)

.....

WHO - Emergency situation reports

Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.

28 January 2025

[Multi-country outbreak of mpox, External situation report #46 - 28 January 2025](#)

.....

Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

[1 February 2025 | Sudan virus disease - Uganda](#)

[29 January 2025 | Zika virus disease - India](#)

.....

Weekly Epidemiological Record

<https://www.who.int/publications/journals/weekly-epidemiological-record>

Vol. 100, Nos. 05, pp. 33–40 31 January 2025

PDF: <https://iris.who.int/bitstream/handle/10665/380351/WER10005-eng-fre.pdf>

:: WHO's Health Emergencies Programme: acute emergencies monthly summary – December 2024

:: WHO global report on public health intelligence activities, 2023

.....

New WHO Publications

<https://www.who.int/publications>

Selected

29 January 2025

[Strategy for optimizing national routine health information systems: strengthening routine health information...](#)

29 January 2025

[Strategy for optimizing national routine health information systems: strengthening routine health information...](#)

29 January 2025

[Impact of the COVID-19 infodemic on frontline workers and health systems: analysis of story-telling approach...](#)

28 January 2025

[WHO Onchocerciasis Technical Advisory Subgroup: report of the seventh meeting, Saly, Senegal, 4 November...](#)

27 January 2025

[Polio transition strategic framework: Monitoring and evaluation](#)

27 January 2025

[Polio transition strategic framework: Global Vision to use polio investments to build strong, resilient...](#)

27 January 2025

[Clinical research landscape of monoclonal antibodies](#)

Overview

Monoclonal antibodies (mAbs) are artificial proteins that mimic the body's natural defences and represent an important medical innovation in modern medicine. They are of proven efficacy in various therapeutic areas such as cancer, immune diseases and infectious diseases, and have become the standard of care for several medical conditions in high-income countries, demonstrating improved outcomes over legacy treatments. This report uses data from WHO's International Clinical Trials Registry Platform (ICTRP) and Global Observatory on Health R&D to provide a comprehensive perspective on the state of monoclonal antibody clinical trials over the period of 2014-2023 (2 066 trials), to understand current clinical research, identify gaps for targeted R&D, and to promote access to mAbs.

27 January 2025

[Digital adaptation kit for immunizations: operational requirements for implementing WHO recommendations...](#)

25 January 2025

Elimination of visceral leishmaniasis as a public health problem in Kenya – progress and challenges

24 January 2025

WHO Malaria Policy Advisory Group: meeting report, 1–3 October 2024

.....

.....

USA – HHS, FDA, CDC

HHS

News

Statement from Dr. Dorothy Fink, Acting Secretary of the U.S. Department of Health and Human Services

January 27, 2025

The U.S. Department of Health and Human Services, through the Office for Civil Rights, is tasked with enforcement of many of our nation's laws that protect the fundamental and unalienable rights of conscience and religious exercise. It shall be a priority of the Department to strengthen enforcement of these laws. To this end, the Office for Civil Rights will reevaluate its regulations and guidance pertaining to Federal laws on conscience and religious exercise.

For nearly 50 years, the Hyde Amendment has protected taxpayer funds administered by the Department from paying for elective abortion. Pursuant to the President's Executive Order of Jan. 24 (Enforcing the Hyde Amendment) and guidance from Office of Management and Budget, the Department will reevaluate all programs, regulations, and guidance to ensure Federal taxpayer dollars are not being used to pay for or promote elective abortion, consistent with the Hyde Amendment. This review will be conducted consistent with guidance issued by the Office of Management and Budget.

The Department celebrates the United States' rejoining of the historic Geneva Consensus Declaration on Promoting Women's Health and Strengthening the Family. The Declaration is based around four pillars: (1) better health for women, (2) the preservation of human life, (3) strengthening of the family as the foundational unit of society, and (4) protecting every nation's national sovereignty. The Office of Global Affairs will support the Secretary of State in restoring the United States' leadership in the Geneva Consensus Declaration coalition.

FDA

Press Announcements

No new digest content identified.

FDA VRBPAC

Advisory Committee Calendar

No new VRBPAC calendar dates identified.

CDC/ACIP [U.S.] [to 01 Feb 2025]

<http://www.cdc.gov/media/index.html>

Latest News

Last news release 10 Jan 2025.

Webpage advisory: "CDC's website is being modified to comply with President Trump's Executive Orders."

ACIP Meetings

Next ACIP Meeting
February 26-27, 2025
Agenda for February 26-28

MMWR Weekly

<https://www.cdc.gov/mmwr/index2024.html>

The January 16th MMWR [below] which we carried in our last edition no longer appears on the MMWR webpage. We note the two ACIP recommended immunization schedules that comprise this edition. The PDF link below is still active.

MMWR Weekly, January 16, 2025 / No. 2

[PDF of this issue](#)

- [Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2025](#)
- [Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2025](#)

.....
.....

Europe

European Medicines Agency [EMA]

<https://www.ema.europa.eu/en/news>

News & Press Releases

[Clinical Trials Regulation becomes fully applicable](#)

Clinical Trials Information System now supports submission, assessment and oversight of all trials in the EU

31 January 2025

[New Chikungunya vaccine for adolescents from 12 and adults](#)

The review of Vimkunya was expedited because of public health interest

31 January 2025

EMA has recommended granting a marketing authorisation in the European Union (EU) for Vimkunya, the first vaccine in the EU to protect adolescents from the age of 12 against Chikungunya. This vaccine, also intended for adults, is given as a single dose.

[Meeting highlights from the Committee for Medicinal Products for Human Use \(CHMP\) 27-30 January 2025](#)

31 January 2025

Eight new medicines recommended for approval; one positive opinion for a medicine intended for use outside the EU

...The CHMP recommended granting a marketing authorisation for Capvaxive (pneumococcal polysaccharide conjugate vaccine (21-valent)), a vaccine intended for the prevention of invasive disease and pneumonia caused by streptococcus pneumoniae bacteria in adults...

The committee recommended granting a marketing authorisation for Vimkunya (chikungunya vaccine (recombinant, adsorbed)), a new vaccine to protect young people from 12 years of age and adults against disease caused by the Chikungunya virus. This medicine was supported through EMA's PRIority MEdicines (PRIME) scheme, which provides early and enhanced scientific and regulatory support for promising medicines with a potential to address unmet medical needs. See more details in the news announcement in the grid below...

European Shortages Monitoring Platform fully operational for monitoring of shortages in the EU

Reporting of medicine shortages by marketing authorisation holders and regulators in one single platform

29 January 2025

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

News/Updates/Reports/Publications [Selected]

Detections of poliovirus in sewage samples require enhanced routine and catch-up vaccination and increased surveillance

30 Jan 2025

Avian influenza: EU agencies track virus mutations and analyse response strategies

29 Jan 2025

Assessment

Assessing the risk to public health of multiple detections of poliovirus in wastewater in the EU/EEA

30 Jan 2025

Between September and December 2024, four countries in the EU/EEA (Finland, Germany, Poland, and Spain) and the United Kingdom (UK) reported detections of a genetic cluster of circulating vaccine-derived poliovirus type 2 (cVDPV2) in sewage samples.

.....

.....

Africa CDC [to 01 Feb 2025]

<https://africacdc.org/>

Press Releases, Statements [Selected]

Call To Action

Africa CDC Urges Immediate Action to Protect Lives Amid Escalating Health and Security Crises

1 February 2025

.....

China CDC+

<http://www.chinacdc.cn/en/>

National Health Commission of the People's Republic of China [to 01 Feb 2025]

<http://en.nhc.gov.cn/>

News

No new digest content identified.

National Medical Products Administration – PRC [to 01 Feb 2025]

<http://english.nmpa.gov.cn/>

News

No new digest content identified.

China CDC

CCDC Weekly Reports: Current Volume (7)

2025-01-31 / No. 5

[PDF of this issue](#)

No new digest content identified.

.....
.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....
.....

Organization Announcements

Paul G. Allen Frontiers Group [to 01 Feb 2025]

<https://alleninstitute.org/news-press/>

News

No new digest content identified.

BMGF - Gates Foundation [to 01 Feb 2025]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases & Statements

Statement Jan 28, 2025

Statement from CEO Mark Suzman: On the Importance of Continued U.S. International Aid

U.S. assistance programs, such as PEPFAR, deliver life-saving medicine, medical care, and combat hunger and starvation. These programs protect the health of Americans, bolster U.S. national security, and build stronger economies. We are committed to working with the Administration on these issues and encourage them to ensure this critical funding continues immediately while their reviews are underway.

Bill & Melinda Gates Medical Research Institute [to 01 Feb 2025]

<https://www.gatesmri.org/news>

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people

News: Articles and Publications

No new digest content identified.

CARB-X [to 01 Feb 2025]

<https://carb-x.org/>

News

01.23.2025 |

CARB-X funds Immunartes to develop Staphylococcus aureus preventative

CARB-X will award Immunartes US\$729k to develop a monoclonal antibody to prevent infections caused by Staphylococcus aureus.

Chan Zuckerberg Initiative [to 01 Feb 2025]

<https://chanzuckerberg.com/newsroom/>

Newsroom

No new digest content identified.

CEPI – Coalition for Epidemic Preparedness Innovations [to 01 Feb 2025]

<http://cepi.net/>

CEPI News, Blog

Blog

[Progressing the 100 Days Mission for greater global health security](#)

A closer look at the progress made towards the 100 Days Mission for vaccines in 2024
30 Jan 2025

Blog

[Bringing together all the pieces of the Lassa fever vaccine puzzle](#)

29 Jan 2025

News

[New CEPI funding to spearhead pandemic preparedness research](#)

26 Jan 2025

...The University of Saskatchewan's (USask) Vaccine and Infectious Disease Organization (VIDO) has been awarded a research grant worth up to \$24 million (Cdn) from the Coalition for Epidemic Preparedness Innovations (CEPI), which aims to support VIDO's role in advancing global health and disease prevention.

The new funding will help VIDO continue developing its pan-sarbecovirus vaccine – a broadly protective vaccine designed specifically to protect against different types of potentially deadly coronaviruses, including SARS-CoV-1, as well as SARS-CoV-2, the virus behind the COVID-19 pandemic. If successful, the candidate vaccine will be tested in a Phase I clinical trial in people...

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 01 Feb 2025]

<https://cioms.ch/>

News; Publications; Events

No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 01 Feb 2025]

<https://www.darpa.mil/news>

News

Jan 31, 2025

[Closing the integration gap for molecules and microsystems](#)

DARPA announced the Microsystem Induced CAtalysis (MICA) program. MICA seeks to develop new approaches for integrating molecular catalysts with...

DNDI – Drugs for Neglected Diseases initiative [to 01 Feb 2025]

<https://dndi.org/press/press-releases/>

Press Releases

Press releases 30 Jan 2025

[DNDi welcomes GHIT support for new collaboration with Eisai for dengue and Zika virus disease](#)

Press releases 30 Jan 2025

[IRD, DNDi and Institut Pasteur welcome the WHO validation for the elimination of sleeping sickness in Guinea](#)

Duke Global Health Innovation Center [to 01 Feb 2025]

<https://dukeghic.org/>

News

No new digest content identified.

EDCTP [to 01 Feb 2025]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

30 January 2025

[EDCTP contributions to ending neglected tropical diseases](#)

In line with the theme of World NTD Day 2025, "Unite. Act. Eliminate," EDCTP reaffirms its commitment to ending neglected tropical diseases (NTDs).

Emory Vaccine Center [to 01 Feb 2025]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [to 01 Feb 2025]

<http://www.euvaccine.eu/>

Latest News, Events

[TRANSVAC: a pillar of vaccine development in Europe for 16 years](#)

The European vaccine development ecosystem has been strengthened over the last 16 years, thanks to the TRANSVAC

31 Jan 2025

Fondation Merieux [to 01 Feb 2025]

<http://www.fondation-merieux.org/>

News, Events

No new digest content identified.

Gavi [to 01 Feb 2025]

<https://www.gavi.org/>

Press Releases

28 January 2025

"la Caixa" Foundation renews its partnership with Gavi with first multi-annual commitment

- The "la Caixa" Foundation has increased its contribution to the Alliance for Child Vaccination to €3 million annually from 2025–2027
- All donations to the Alliance for Child Vaccination will continue to be quadrupled through the matching fund formula 1=4, thanks to contributions from the "la Caixa" Foundation and the Gates Foundation
- To date, this initiative has raised over €100 million, enabling the immunisation of millions of children – primarily against pneumonia – in highly vulnerable areas of Africa that lack access to vaccines

GE2P2 Global Foundation [to 01 Feb 2025]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements

:: [Vaccines and Global Health: The Week in Review](#) - Current edition

:: [Informed Consent: A Monthly Review – January 2025](#)

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 14 Jan 2025](#)

GHIT Fund [to 01 Feb 2025]

<https://www.ghitfund.org/newsroom/press>

Press Releases

January 30, 2025

A Total of USD 12.7 Million Investment in New Diagnostics and Drug Development for NTDs and Malaria to Partners including The Ohio State University, PATH, GSK and Others

Global Fund [to 01 Feb 2025]

<https://www.theglobalfund.org/en/news/>

News Releases

No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 01 Feb 2025]

<https://www.glopid-r.org/news/>

News

No new digest content identified.

Hilleman Laboratories [to 01 Feb 2025]

<http://www.hilleman-labs.org/>

News & Insights

No new digest content identified.

HHMI - Howard Hughes Medical Institute [to 01 Feb 2025]

<https://www.hhmi.org/news>

Press Room

Edith Heard Elected as HHMI Trustee

January 30, 2025

Professor Edith Heard, Director General of the European Molecular Biology Laboratory, has been elected a Trustee of the Howard Hughes Medical Institute (HHMI), the largest private biomedical research institution in the United States. Her appointment will begin on February 1, 2025.

Human Immunome Project [nee Human Vaccines Project] [to 01 Feb 2025]

<https://www.humanimmunomeproject.org/>

News

No new digest content identified.

IAVI [to 01 Feb 2025]

<https://www.iavi.org/>

Press Releases

No new digest content identified.

INSERM [to 01 Feb 2025]

<https://www.inserm.fr/en/home/>

Press Releases

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use] [to 01 Feb 2025]

<https://www.ich.org/>

News/Pubs/Press Releases [Selective]

No new digest content identified.

ICRC [to 01 Feb 2025]

<https://www.icrc.org/en/whats-new>

What's New [Selected]

Statement 28-01-2025

[Every human life deserves safety and dignity: A call to make international humanitarian law a political priority](#)

IFFIm

<http://www.iffim.org/>

Press Releases/Announcements

Statement 28-01-2025

[Every human life deserves safety and dignity: A call to make international humanitarian law a political priority](#)

IFRC [to 01 Feb 2025]

<http://media.ifrc.org/ifrc/news/press-releases/>

Press Releases [Selected]

No new digest content identified.

IPPS - International Pandemic Preparedness Secretariat

<https://ippsecretariat.org/news/>

News

[The world remains unprepared for another global pandemic, despite national bright spots, as the 4th Implementation Report of the 100 Days Mission is launched in Cape Town](#)

January 30, 2025

Institut Pasteur [to 01 Feb 2025]

<https://www.pasteur.fr/en/press-area>

Press Documents

Press Info 31.01.2025

[IRD, DNDi, Institut Pasteur de Guinée and the Institut Pasteur welcome the WHO validation for the elimination of sleeping sickness in Guinea](#)

Guinea celebrates today the elimination of sleeping sickness (also known as human African trypanosomiasis or HAT) as a...

ISC / International Science Council [to 01 Feb 2025]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

Latest Updates

30 January 2025 - 4 min read

[ISC General Assembly 2025 concludes with strategic vision for global science](#)

The International Science Council (ISC) has concluded its Third General Assembly, bringing together ISC Member delegates, Fellows, and scientific representatives for two days of strategic discussions. Hosted by the Sultanate of Oman, the Assembly served as a pivotal moment for shaping the future of international science cooperation.

news

30 January 2025 - 4 min read

[Robbert Dijkgraaf, renowned mathematical physicist, named President-Elect of the International Science Council](#)

Robbert Dijkgraaf, former Dutch Minister and renowned scientist, assumes office as President-Elect of the International Science Council.

news

29 January 2025 - 2 min read

[United Nations Secretary-General's message to the International Science Council](#)

news

29 January 2025 - 5 min read

ISC Third General Assembly opens in Muscat

news

28 January 2025 - 6 min read

Muscat Dialogue closes with a collective call for action to leverage science for the global good

Over 415 representatives from 132 countries gathered in Oman to discuss science's role in advancing sustainability and global development. The event concluded with the adoption of the Muscat Declaration, a call to action for equitable access to knowledge, transformative science systems, and strengthened international collaboration to address pressing global challenges.

news

28 January 2025 - 7 min read

The Muscat Declaration on Global Science

International Union of Immunological Societies (IUIS)

<https://iuis.org/>

News/Events [Selected]

19th International Congress of Immunology

Vienna, August 17-22, 2025.

IVAC [to 01 Feb 2025]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

2024 Pneumonia & Diarrhea Progress Report Card

IVI [to 01 Feb 2025]

<http://www.ivi.int/>

IVI News & Announcements

No new digest content identified.

Johns Hopkins Center for Health Security [to 01 Feb 2025]

<https://centerforhealthsecurity.org/newsroom>

Center News [Selected]

No new digest content identified.

MSF/Médecins Sans Frontières [to 01 Feb 2025]

<http://www.msf.org/>

Latest [Selected Announcements]

Democratic Republic of Congo

A chaotic situation and many war-wounded in Goma

Voices from the Field 31 Jan 2025

Pakistan

Turning the tide of hepatitis C treatment in Machar Colony

Project Update 30 Jan 2025

Neglected diseases

Four diseases you've probably never heard of

Project Update 30 Jan 2025

Democratic Republic of Congo

MSF appeals for humanitarian access in Goma as casualties seek medical care

Press Release 29 Jan 2025

National Academy of Medicine - USA [to 01 Feb 2025]

<https://nam.edu/programs/>

News [Selected]

No new digest content identified.

National Academies-Sciences-Engineering-Medicine [NASEM]- USA [to 01 Feb 2025]

<https://www.nationalacademies.org/newsroom>

News

No new digest content identified.

National Vaccine Program Office - U.S. HHS [to 01 Feb 2025]

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

No new digest content identified.

NIH [to 01 Feb 2025]

<http://www.nih.gov/>

News Releases

Last announcement: 17 January 2025

PATH [to 01 Feb 2025]

<https://www.path.org/media-center/>

Newsroom

Accelerating progress towards maternal, neonatal, and child health

January 22, 2025 by PATH

The maternal, newborn, and child mortality burden in West and Central Africa remains among the highest in the world, demanding urgent, targeted and accelerated efforts.

Sabin Vaccine Institute [to 01 Feb 2025]

<https://www.sabin.org/press/>

Latest News & Press Releases

No new digest content identified.

UNAIDS [to 01 Feb 2025]

<http://www.unaids.org/en>

News, Stories, Updates

Press release

UNAIDS urges that all essential HIV services must continue while U.S. pauses its funding for foreign aid

GENEVA, 1 February 2025— The Joint United Nations Programme on HIV/AIDS (UNAIDS) is urging for a continuation of all essential HIV services while the United States pauses its funding for foreign aid.

On 29 January, UNAIDS welcomed the news that United States Secretary of State, Marco Rubio, had approved an “Emergency Humanitarian Waiver,” allowing people to continue accessing lifesaving HIV treatment funded by the U.S. in 55 countries worldwide. More than 20 million people - two-thirds of all people living with HIV accessing HIV treatment globally - are directly supported by the United States President’s Emergency Plan for AIDS Relief (PEPFAR)...

UNICEF [to 01 Feb 2025]

<https://www.unicef.org/media/press-releases>

Latest press releases, news notes and statements

Press release 27 January 2025

Scaling up supplies and services for children in the Gaza Strip

NEW YORK, 27 January 2025 – UNICEF has accelerated the distribution of supplies and services to children in the Gaza Strip, with more than 350 trucks entering in the first week of the long-awaited ceasefire...

UNICEF is focused on providing vaccines and support teams for immunization catch-up activities to prevent disease outbreaks, while expanding and scaling up the screening and treatment of malnutrition. Hospitals in the Gaza Strip, especially in the north, will receive support to increase their capacity, especially in neonatal units.

UNICEF will increase support for the production of safe water and sanitation and will raise awareness among children and caregivers of the risks they face moving through Gaza, including unexploded ordnance and family separation. UNICEF is also striving to reach families with child protection services, MHPSS support, multi-purpose cash assistance and, ultimately, ensuring all school-age children have access to education...

Unitaid [to 01 Feb 2025]

<https://unitaid.org/>

Featured News

Opinions

Unitaid’s Early Market Access Vehicle – an innovative demand-driven model to catalyze introduction of new optimal health products in low- and middle-income countries

08 January 2025

Vaccine Equity Cooperative [nee Initiative] [to 01 Feb 2025]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin] [to 01 Feb 2025]

<https://www.vaccineacceptance.org/>

No new digest content identified.

Vaccine Confidence Project [to 01 Feb 2025]

<http://www.vaccineconfidence.org/>
News, Research and Reports
No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 01 Feb 2025]

<http://www.chop.edu/centers-programs/vaccine-education-center>
News
No new digest content identified.

Wellcome Trust [to 01 Feb 2025]

<https://wellcome.org/news/all>
News. Opinion, Reports
Explainer

Genomics: how unlocking our genes is transforming healthcare

29 January 2025 5-minute read

Genomics is revolutionising modern medicine. From improving cancer treatments to predicting diseases using genetic information, here are four ways our health is benefitting from genomics.

The Wistar Institute [to 01 Feb 2025]

<https://www.wistar.org/news/press-releases>
Press Releases
No new digest content identified.

World Bank [to 01 Feb 2025]

<http://www.worldbank.org/en/news/all>
All News [Selected]

Commitment to Action on Foundational Learning

Nearly six-out-of-ten children globally are estimated to be affected by learning poverty, meaning they are unable to read and understand a simple text by the age of ten. In low- and middle-income countries...

Date: January 31, 2025 Type: Brief

Digital Pathways for Education: Enabling Greater Impact for All

Event: Report Launch | January 29, 2025 | 8:00 - 9:30 AM EST

Date: January 29, 2025 Type: Publication

WFPHA: World Federation of Public Health Associations [to 01 Feb 2025]

<https://www.wfpha.org/>
Blog, Events
No new digest content identified.

World Medical Association [WMA] [to 01 Feb 2025]

<https://www.wma.net/news-press/press-releases/>
Press Releases
No new digest content identified.

World Organisation for Animal Health [OIE] [to 01 Feb 2025]

<https://www.oie.int/>

Press Releases, Statements

No new digest content identified.

.....

.....

ARM [Alliance for Regenerative Medicine] [to 01 Feb 2025]

<https://alliancerm.org/press-releases/>

Selected Press Releases

No new digest content identified.

BIO [to 01 Feb 2025]

<https://www.bio.org/press-releases>

Press Releases

No new digest announcements identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 01 Feb 2025]

<http://www.dcvmn.org/>

News; Upcoming events

WHO Prequalification for SPbSRIVS and Instituto Mechnikov's FLU-M Influenza Vaccine

January 23, 2025

...FLU-M is now the first Russian influenza vaccine to receive WHO prequalification and is officially recommended for purchase by UN agencies such as the Pan American Health Organization Revolving Fund and UNICEF...For more details on the WHO prequalification and vaccine product:

<https://extranet.who.int/prequal/vaccines/p/flu-mr>

ICBA – International Council of Biotechnology Associations [to 01 Feb 2025]

<https://internationalbiotech.org/news/>

News

No new digest announcements identified.

IFPMA [to 01 Feb 2025]

<https://ifpma.org/>

News, Statements [Selected]

Position paper 17 January 2025

Pharmacy-mediated substitution for biosimilars

By IFPMA

This position paper addresses substitution relating to biosimilars and their reference products at the retail pharmacy level.

International Alliance of Patients' Organizations – IAPO [to 01 Feb 2025]

<https://www.iapo.org.uk/news>

Press and media [Selected]

No new digest announcements identified.

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

No new digest announcements identified.

PhRMA [to 01 Feb 2025]

<http://www.phrma.org/>

Press Releases

PhRMA Congratulates President Donald Trump on His Inauguration

January 20, 2025

...The pharmaceutical industry is the crown jewel of the American economy, giving American patients more treatment options than anywhere else in the world while supporting millions of high-paying, high-tech jobs around the country. Through innovation we've achieved significant breakthroughs, improved cancer survival rates, cured hepatitis C, **and eradicated devastating diseases like polio and smallpox**. New medicines are transforming our ability to prevent, treat, and cure deadly diseases more effectively, improving patient lives and reducing reliance on the most expensive parts of the health care system...

Editor's Note:

We included the PhRMA press release above in last week's edition. When we visited the PhRMA site today to review and include any new announcements, this press release had been deleted. The link in the title of the press release above – active last week – now produces a 404 error. We did not identify any explanation for this deletion action on the PhRMA website..

.....

.....

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

AstraZeneca

Press Releases - *No new digest content identified.*

Bavarian Nordic

Latest News

Bavarian Nordic Receives Positive CHMP Opinion for Chikungunya Vaccine for Persons Aged 12 and Older

- First chikungunya vaccine recommended by the CHMP for persons as young as 12 years old.
- The virus-like particle (VLP) single-dose chikungunya vaccine is expected to launch in key European markets in the first half of 2025, pending final marketing authorization.

January 31, 2025

Bharat Biotech

Press Releases - *No new digest announcements identified*

BioCubaFarma – Cuba

Últimas Noticias - *No new digest announcements identified*

Biological E

News - *No new digest announcements identified*

BioNTech

Press Releases - No new digest announcements identified.

Boehringer

Press Releases - No new digest announcements identified.

CanSinoBIO

News - Website not responding at inquiry

CIGB

Latest News - No new digest announcements identified.

Cinnagen

Recent News - No new digest announcements identified.

Clover Biopharmaceuticals – China

News - No new digest announcements identified.

Curevac

News - No new digest announcements identified.

Gamaleya National Center/Sputnik

Latest News and Events - No new digest announcements identified [Last: 09 Nov 2020]

<https://sputnikvaccine.com/> - No new digest announcements identified [Last: 31 Aug 2022]

GSK

Press releases for media

31 January 2025

[European Commission authorises ViiV Healthcare's long-acting injectable Vocabria + Rekambys for HIV Vocabria + Rekambys \(cabotegravir + rilpivirine\) is the first and only complete long-acting injectable for the treatment of HIV](#)

:: Ninety-nine percent of adolescents living with HIV preferred the long-acting injectable to a daily oral regimen when given the option due to convenience and pill burden reduction

:: This Marketing Authorisation builds on company legacy of expanding access to medicines for children and young people

31 January 2025

[GSK's Shingrix new prefilled syringe presentation accepted for review by European Medicines Agency](#)

:: If approved, the new presentation will offer a convenient administration option to healthcare professionals

:: Globally, up to 1 in 3 adults will develop shingles in their lifetime^{1,2,3,4}

:: Over 25 million people in Europe have received GSK's shingles vaccine since 20185

EuBiologics, S Korea

News - No new digest announcements identified.

IMBCAMS, China

Home - Website not responding at inquiry.

JNJ Innovative Medicine [Janssen]

Press Releases - No new digest announcements identified.

Merck

News releases

[Merck Receives Positive EU CHMP Opinion for CAPVAXIVE™ \(Pneumococcal 21-valent Conjugate Vaccine\) for Pneumococcal Vaccination in Adults](#)

January 31, 2025

Moderna

Press Releases - No new digest announcements identified

Nanogen

News - No new digest announcements identified

Novartis

News - No new digest announcements identified.

Novavax

Press Releases - No new digest announcements identified.

Pfizer

Recent Press Releases - No new digest announcements identified.

R-Pharm

<https://rpharm-us.com/index.php>

[No news or media page identified]

Sanofi Pasteur

Press Releases - No new digest announcements identified.

Serum Institute

News & Announcements - No new digest announcements identified.

Sinopharm/WIBPBIBP

News - No new digest announcements identified.

Sinovac

Press Releases - No new digest announcements identified.

SK Biosciences

Press Releases - No new digest announcements identified.

Takeda

Newsroom

[Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026](#)

January 30, 2025

Valneva

Press Releases

January 30, 2025

[Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of \\$32.8 Million](#)

...Under this new one-year contract, the DoD will buy a minimum of \$32.8 million worth of IXIARO[®] vaccines and has the possibility to purchase additional doses during the coming twelve months. Deliveries of IXIARO[®] doses have continued in 2024 under the supply contract signed in September 2023[1]. The new contract will commence immediately.

Vector State Research Centre of Virology and Biotechnology

Home - [Website not responding [404 error]]

WestVac Biopharma

Media - No new digest announcements identified.

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

Website [No News/Announcements page identified]

.....
.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....
.....

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 16, 2025 Issue 1

<https://www.tandfonline.com/toc/uabr21/current>

Article

[Ethical Issues in Implementation Science: A Qualitative Interview Study of Participating Clinicians](#)

Justin T. Clapp, Naomi Zucker, Olivia K. Hernandez, Ellen J. Bass & Meghan B. Lane-Fall

Pages: 22-31

Published online: 13 Aug 2024

Article

[Supporting Stewardship: Funding, Utilization, and Sustainability as Ethical Concerns in Networked Biobanking](#)

R. Jean Cadigan, Roselle Ponsaran, Carla Rich, Josie Timmons, Kyle B. Brothers & Aaron J. Goldenberg

Pages: 42-51
Published online: 09 Sep 2024

AMA Journal of Ethics

Volume 27, Number 2: E67-166 Feb 2025

<https://journalofethics.ama-assn.org/issue/epidemiology-and-clinical-practice>

Issue Theme: Pain Management in Non-Labor and Delivery OBGYN Procedures

American Journal of Human Genetics

Jan 02, 2025 Volume 112 Issue 1 p1-198

<https://www.cell.com/ajhg/current>

This month in The Journal

Alyson B. Barnes, Kylee L. Spencer, Sara B. Cullinan

Loss-of-function variants are typically considered in terms of gene-specific, pathway-dependent effects. An altered protein is produced, affecting the protein-specific pathway or a related phenotype. However, characterizing the gene-specific, pathway-dependent effects alone does not always explain the phenotypic variability observed between individuals with the same mutation or predict disease trajectory. In this issue, Shovlin and Aldred present a parallel paradigm for loss-of-function variants based on proteostasis, the process of maintaining a healthy balance of proteins within a cell.

American Journal of Infection Control

February 2025 Volume 53 Issue 2 p175-284

<http://www.ajicjournal.org/current>

Major Articles

[Infection Prevention and Control Response and Escalation Framework: Evaluation and application beyond a pandemic](#)

Kathy Dempsey, et al.

Published online: November 07, 2024

p188-195 Open Access

[Health care workers' perceptions about infection prevention and control in Latin America](#)

Valeria Fabre, et al.

Published online: October 09, 2024

p222-227

American Journal of Preventive Medicine

February 2025 Volume 68 Issue 2 p217-428

<https://www.ajpmonline.org/current>

[New issue; No digest content identified]

American Journal of Public Health

February 2025 115(2)

<http://ajph.aphapublications.org/toc/ajph/current>

OPEN-THEMED RESEARCH

[Influenza Vaccination, Household Composition, and Race-Based Differences in Influenza Incidence: An Agent-Based Modeling Study](#)

Katherine V. Williams MD, MPH, Mary G. Krauland PhD, Lee H. Harrison MD, John V. Williams MD, Mark S. Roberts MD, MPP and Richard K. Zimmerman MD, MPH
115(2), pp. 209–216

American Journal of Tropical Medicine and Hygiene

Volume 112 (2025): Issue 1 (Jan 2025)

<https://www.ajtmh.org/view/journals/tpmd/111/4/tpmd.112.issue-1.xml>

[Reviewed earlier]

Annals of Internal Medicine

January 2025 Volume 178, Issue 1

<https://www.acpjournals.org/toc/aim/current>

[Reviewed earlier]

Artificial Intelligence – An International Journal

Volume 338 January 2025

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/338/suppl/C>

[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 01 Feb 2025)

[No new digest content identified]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 01 Feb 2025)

[Perspectives of medical sciences students regarding COVID-19 vaccination: a cross-sectional study](#)

The perspectives of medical sciences students regarding COVID-19 vaccination are crucial as they are future healthcare providers who will influence public health outcomes and vaccination rates. The objective o...

Authors: Maryam Aghabarary, Mahsa Khedmatizare and Roohangiz Norouzinia

Citation: *BMC Health Services Research* 2025 25:191

Content type: Research Published on: 1 February 2025

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 01 Feb 2025)

[Critical assessment of uncertainty in economic evaluations on influenza vaccines for the elderly population in Spain](#)

Influenza is a seasonal infection with a huge impact on morbidity and mortality in older adults, for whom vaccination is recommended. New influenza vaccines for this population have been introduced in Spain in...

Authors: Raúl Ortiz-de-Lejarazu Leonardo, Javier Díez Domingo, Ángel Gil de Miguel, Federico Martínón Torres, Esther Redondo Margüello, Juan Luis López-Belmonte Claver, Paloma I. Palomo-Jiménez, J. Manel Farré Avellà and José María Abellán Perpiñán
Citation: BMC Infectious Diseases 2025 25:152
Content type: Research Published on: 1 February 2025

[Prevalence of non-vaccine high-risk HPV cervical infections in vaccinated women: a systematic review and meta-analysis](#)

Human Papillomavirus (HPV) is the most common sexually transmitted lower genital tract infection worldwide and the main etiological factor of cervical cancer (CC). Since 2006, vaccines have been implemented to...

Authors: Glauciane Resende do Nascimento, Ana Carolina da Silva Santos, Nayara Nascimento Toledo Silva, Nathalia Sernizon Guilmarães, Angélica Alves Lima and Wendel Coura-Vital
Citation: BMC Infectious Diseases 2025 25:131
Content type: Systematic Review Published on: 28 January 2025

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 01 Feb 2025)

[No new digest content identified]

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 01 Feb 2025)

[No new digest content identified]

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 01 Feb 2025)

[No new digest content identified]

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 01 Feb 2025)

[Strategies and resources used by public health units to encourage COVID-19 vaccination among priority groups: a behavioural science-informed review of three urban centres in Canada](#)

Ensuring widespread COVID-19 vaccine uptake is a public health priority in Canada and globally, particularly within communities that exhibit lower uptake rates and are at a higher risk of infection. Public hea...

Authors: Tori Langmuir, Mackenzie Wilson, Nicola McCleary, Andrea M. Patey, Karim Mekki, Hanan Ghazal, Elizabeth Estey Noad, Judy Buchan, Vinita Dubey, Jana Galley, Emily Gibson, Guillaume Fontaine, Maureen Smith, Amjad Alghamyan, Kimberly Thompson, Jacob Crawshaw...

Citation: BMC Public Health 2025 25:403

Content type: Research Published on: 31 January 2025

[Prevalence and associated factors of parental refusal rates for routine immunisation: a cross-sectional study in Peshawar, Khyber Pakhtunkhwa, Pakistan-2024](#)

Vaccine hesitancy is a serious public health problem globally, particularly in low- and middle-income countries like Pakistan. This study aims to determine the vaccination refusal rate, associated factors and ...

Authors: Muhammad Hakim, Farhad Ali, Zala, Aslam Pervaiz, Saima Afaq and Zia ul Haq

Citation: BMC Public Health 2025 25:369

Content type: Research Published on: 29 January 2025

BMC Research Notes

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 01 Feb 2025)

[No new digest content identified]

BMJ Evidence-Based Medicine

February 2025 - Volume 30 - 1

<https://ebm.bmj.com/content/30/1>

[Reviewed earlier]

BMJ Global Health

December 2024 - Volume 9 - 12

<https://gh.bmj.com/content/9/12>

[Reviewed earlier]

Bulletin of the World Health Organization

Volume 103, Number 1, January 2025, 1-80

<https://www.who.int/publications/journals/bulletin/>

In this month's Bulletin

In the editorial section, Katherine Littler et al. (2) call for papers for a special theme issue on the ethics of research into health and climate change.

Gary Humphreys (5–6) reports on initiatives to mitigate unintended consequences of health policies. Glenda Gray talks to Humphreys (7–8) about her career working on HIV prevention and treatment.

[Reviewed earlier]

Cell

Jan 23, 2025 Volume 188 Issue 2 p273-572

<https://www.cell.com/cell/current>

[New issue; No digest content identified]

Child Care, Health and Development

Volume 51, Issue 1 January 2025

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 117, Issue 2 Pages: 311-598 February 2025

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

Perspective

Artificial Intelligence in European Medicines Regulation: From Vision to Action. Harnessing the Capabilities of Artificial Intelligence for the Benefit of Public and Animal Health

Luis Correia Pinheiro, Peter Arlett, Kit Roes, Flora Musuamba Tshinanu, Gabriel Westman, Zaide Frias, Hilmar Hamann, Joaquim Berenguer Jornet, Iftekhar Khan, Jeppe Larsen, Karl Broich, Emer Cooke

Pages: 335-336

First Published: 22 November 2024

Clinical Therapeutics

January 2025 Volume 47 Issue 1 p1-114

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

Clinical Trials

Volume 21 Issue 6, December 2024

<https://journals.sagepub.com/toc/ctja/21/6>

[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 01 Feb 2025]

[No new digest content identified]

Contemporary Clinical Trials

Volume 148 January 2025

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/147/suppl/C>

[Reviewed earlier]

The CRISPR Journal

Volume 7, Issue 6 / December 2024

<https://www.liebertpub.com/toc/crispr/7/6>

[Reviewed earlier]

Current Genetic Medicine Reports

Volume 11, Issue 3-4 December 2023

<https://link.springer.com/journal/40142/volumes-and-issues/11-3>

[Reviewed earlier]

Current Medical Research and Opinion

Volume 40, Issue 12 2024

<https://www.tandfonline.com/toc/icmo20/current>

[New issue; No digest content identified]

Current Opinion in Infectious Diseases

February 2025 - Volume 38 - Issue 1

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

Current Protocols in Human Genetics

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 01 Feb 2025]

[No new digest content identified]

Developing World Bioethics

Volume 24, Issue 4 Pages: 263-342 December 2024

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

Development in Practice

Volume 34, Issue 6, 2024

<https://www.tandfonline.com/toc/cdip20/34/6>

[Reviewed earlier]

Development Policy Review

Volume 43, Issue 2 March 2025

<https://onlinelibrary.wiley.com/toc/14677679/current>

[New issue; No digest content identified]

Disaster Medicine and Public Health Preparedness

Volume 18 - 2024

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

Disasters

Volume 49, Issue 1 January 2025

<https://onlinelibrary.wiley.com/toc/14677717/2025/49/1>

[Reviewed earlier]

EMBO Reports

Volume 26 Issue 1 10 January 2025

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

Emerging Infectious Diseases

Volume 31, Number 1—January 2025

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

Epidemics

Volume 49 December 2024

<https://www.sciencedirect.com/journal/epidemics/vol/49/suppl/C>

[Reviewed earlier]

Epidemiology and Infection

Volume 153 - 2025

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 46, Issue 6 Pages: 1-35 November–December 2024

<https://onlinelibrary.wiley.com/toc/25782363/current>

Data monitoring committee insights / Ethics reviews and AI tools

[Reviewed earlier]

Ethics & International Affairs

Volume 38 - Issue 3 - Fall 2024

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>

[Reviewed earlier]

Ethics, Medicine and Public Health

Volume 32 2024

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/32/suppl/Cc>

[Reviewed earlier]

The European Journal of Public Health

Volume 34, Issue 6, December 2024

<https://academic.oup.com/eurpub/issue/34/6>

Health Policy

[Constructing a One Health governance architecture: a systematic review and analysis of governance mechanisms for One Health](#)

Darlington David Faijue and others

[Burden of disease studies supporting policymaking in the European Union: a systematic review](#)

José Chen-Xu and others

[An integrated pathway for influenza vaccination across primary and secondary care using a clinical decision support system: model definition and predictive impact analysis](#)

Maria Lucia Specchia and others

Expert Review of Vaccines

Volume 24, 2025 Issue 1
<https://www.tandfonline.com/toc/ierv20/current>
[Reviewed earlier]

Foreign Affairs

January/February 2025
<https://www.foreignaffairs.com/issues/2025/104/1>
Special Section
Will Trump Change the World?

Forum for Development Studies

Volume 51, 2024 - Issue 3
<http://www.tandfonline.com/toc/sfds20/current>
[Reviewed earlier]

Frontiers in Medicine

<https://www.frontiersin.org/journals/medicine/volumes?volume-id=1237>
[Accessed 01 Feb 2025]
Original Research Published on 27 Jan 2025
[A national framework for transition to precision medicine](#)
Samaneh Karimi Esboei, Sepehr Ghazinoory, Fatemeh Saghafi

Gene Therapy – Nature

Volume 32 Issue 1, January 2025
<https://www.nature.com/gt/volumes/32/issues/1>
Editorial 11 Nov 2024
[The disparate burden of infectious diseases](#)
Kristie Bloom

Perspective Open Access 18 Nov 2024
[Bridging gene therapy and next-generation vaccine technologies](#)
Kristie Bloom, Abdullah Ely, Patrick Arbuthnot
[*Excerpt*]

...A point, perhaps not made frequently enough, is that the Spike protein of SARS-CoV-2 turned out to be an easy target for vaccine development and was based on years of research on similar Betacoronavirus prototype pathogens [33]. Other viruses often do not present such convenient immunogenic antigens. Repeated failure of HIV-1 vaccine development has shown this. However, demonstration that anti-SARS-CoV-2 mRNA vaccines may be mass-produced for global immunization programs was an important milestone. Extrapolation of current gene-based vaccine technology to counter different infections is an exciting prospect. Also, ensuring that vaccines are robust and affordable will be vital to improve global access. Research on gene therapy and other topics will continue to complement advances with vaccine development. Currently there is significant global resolve to use multifaceted systems to tackle existing problems of pandemic preparedness. The field of gene-based vaccination has impetus and will no doubt witness significant breakthroughs soon.

Review Article Open Access 22 Jul 2024
[Gene drives: an alternative approach to malaria control?](#)
Kubendran Naidoo, Shüné V. Oliver

Genetics in Medicines

Volume 27, Issue 1 January 2025

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/27/issue/1>

[Reviewed earlier]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 01 Feb 2025]

[No new digest content identified]

Global Health Action

Volume 17, Issue 1 (2024)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 12, No. 6 December 20, 2024

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

Global Legal Monitor & Legal Reports – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>

https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc

[Accessed 01 Feb 2025]

[No new digest content identified]

Global Public Health

Volume 20, Issue 1 (2025)

<http://www.tandfonline.com/toc/rqph20/current>

[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 01 Feb 2025]

States, global power and access to medicines: a comparative case study of China, India and the United States, 2000–2019

What constitutes state's global power to shape access to medicines? How was it distributed between states and how did this change from 2000 to 2019? In this comparative case study, we explored the powers of China, India and the United States, and discuss whether our findings from the pre-pandemic era were reflected in the global COVID-19 response related to pharmaceuticals. We used an analytical framework from the international relations literature on structural power, and assessed the following power structures after adapting them to the context of access to medicines: finance, production, financial protection, knowledge, trade and official development assistance.

Authors: Berit S. H. Hembre, Maulik Chokshi, Steven J. Hoffman, Fatima Suleman, Steinar Andresen, Kristin Sandberg and John-Arne Røttingen
Citation: *Globalization and Health* 2025 21:3
Content type: Research Published on: 1 February 2025

Health and Human Rights

Volume 26, Issue 2, December 2024

<https://www.hhrjournal.org/volume-26-issue-2-december-2024/>

Special Section: Distress Migration and the Right to Health

[Reviewed earlier]

Health Economics, Policy and Law

Volume 19 - Issue 3 - July 2024

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/>

[Reviewed earlier]

Health Policy and Planning

Volume 39, Issue 10, December 2024

<https://academic.oup.com/heapol/issue/39/10>

[Reviewed earlier]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 01 Feb 2025]

[No new digest content identified]

Human Gene Therapy

Volume 36, Issue 1-2 / January 2025

<https://www.liebertpub.com/toc/hum/36/1-2>

[Reviewed earlier]

Humanitarian Practice Network

<https://odihpn.org/>

Featured Publications

[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 20 Issue 1, 2024

<https://www.tandfonline.com/toc/khvi20/20/1?nav=tocList>

Selected Content

[Reviewed earlier]

Immunity

Jan 14, 2025 Volume 58 Issue 1 p1-264

<https://www.cell.com/immunity/current>
[Reviewed earlier]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/>
[Accessed 01 Feb 2025]
[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournals.com/content>
[Accessed 01 Feb 2025]
[No new digest content identified]

International Health

Volume 17, Issue 1, January 2025
<https://academic.oup.com/inthealth/issue/17/1>
[Reviewed earlier]

International Human Rights Law Review

Volume 13 (2024): Issue 2 (Dec 2024)
<https://brill.com/view/journals/hrlr/13/2/hrlr.13.issue-2.xml>
[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol. 12 No. 1 (2025): January 2025
<https://www.ijcmph.com/index.php/ijcmph/issue/view/120>
<https://academic.oup.com/ije/issue/53/6>
[Reviewed earlier]

International Journal of Epidemiology

Volume 53, Issue 6, December 2024
<https://academic.oup.com/ije/issue/53/6>
[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 17 Issue 4 2024
<https://www.emerald.com/insight/publication/issn/2056-4902/vol/17/iss/4>
Table of contents
[Reviewed earlier]

JAMA

January 28, 2025, Vol 333, No. 4, Pages 271-358
<https://jamanetwork.com/journals/jama/currentissue>
Original Investigation

HepB-CpG vs HepB-Alum Vaccine in People With HIV and Prior Vaccine NonresponseThe BEE-HIVe Randomized Clinical Trial

Kristen M. Marks, MD; Minhee Kang, PhD; Triin Umbleja, MSc; et al.

JAMA. 2025;333(4):295-306. doi:10.1001/jama.2024.24490

This randomized clinical trial compares the seroprotection response achieved with a 2-dose and a 3-dose hepatitis B vaccine with a cytosine phosphoguanine adjuvant vs a conventional 3-dose hepatitis B vaccine with an aluminum hydroxide adjuvant in people with HIV and prior nonresponse to hepatitis B vaccine.

Editorial

Overcoming Hepatitis B Vaccine Nonresponsiveness

Ivan Hung, MD; Anna S. Lok, MD

AI in Medicine

Testing and Evaluation of Health Care Applications of Large Language Models-A Systematic Review

Suhana Bedi, BA; Yutong Liu, MA; Lucy Orr-Ewing, BA; et al.

free access has active quiz

JAMA. 2025;333(4):319-328. doi:10.1001/jama.2024.21700

This systematic review characterizes the current performance of large language models in evaluating clinical health care settings, including uniformity, thoroughness, and robustness and proposes a framework for their testing and evaluation across health care applications.

Viewpoint

The Urgent Case for Recommitting to Global HIV/AIDS Goals

Carlos del Rio, MD; Victor Dzau, MD

JAMA. 2025;333(4):281-282. doi:10.1001/jama.2024.26348

This Viewpoint discusses the need to recommit to the fight against HIV/AIDS to reach the United Nation's 2030 goal of ending the epidemic as a public health threat.

JAMA Health Forum

January 2025, Vol 6, No. 1

<https://jamanetwork.com/journals/jama-health-forum/issue>

[Reviewed earlier]

JAMA Pediatrics

January 2025, Vol 179, No. 1, Pages 3-108

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[New issue; No digest content identified]

JBIR Evidence Synthesis

January 2025 - Volume 23 - Issue 1

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[New issue; No digest content identified]

Journal of Adolescent Health

January 2025 Volume 76 Issue 1 p1-172

<https://www.jahonline.org/current>

[Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 81 (2024)

<https://www.jair.org/index.php/jair>

Contents

[Reviewed earlier]

Journal of Community Health

Volume 49, Issue 6 December 2024

<https://link.springer.com/journal/10900/volumes-and-issues/49-6>

[Reviewed earlier]

Journal of Current Medical Research and Opinion

...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.

Vol. 7 No. 11 (2024)

<https://www.cmro.in/index.php/jcmro/issue/view/89>

[Reviewed earlier]

Journal of Development Economics

Volume 172 January 2025

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/172/suppl/C>

[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 19 Issue 4-5, October–December 2024

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

Journal of Epidemiology & Community Health

December 2024 - Volume 78 - 12

<https://jech.bmj.com/content/78/12>

[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 17, Issue 4 Pages: 689-873 December 2024

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

Journal of Global Ethics

Volume 20, Issue 3 (2024)

<http://www.tandfonline.com/toc/rjge20/current>

Special Issue: 20th Anniversary Forum

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 35, Number 4, November 2024

<https://muse.jhu.edu/issue/53739>

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 26, Issue 6 December 2024

<https://link.springer.com/journal/10903/volumes-and-issues/26-6>

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 22, 2024 _ Issue 4

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of International Development

Volume 37, Issue 1 Pages: 1-349 January 2025

<https://onlinelibrary.wiley.com/toc/10991328/current>

[Reviewed earlier]

Journal of Medical Ethics

January 2025 - Volume 51 - 1

<http://jme.bmj.com/content/current>

[Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 11, Issue 3 (2024)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

The Journal of Pediatrics

Volume 275 December 2024

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/275/suppl/C>

[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

Volume 17, Issue 1 (2024)

<https://www.tandfonline.com/toc/jppp20/17/1>

[Reviewed earlier]

Journal of Public Health Management & Practice

January/February 2025 - Volume 31 - Issue 1

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Public Health Policy

Volume 45, issue 4, December 2024

<https://link.springer.com/journal/41271/volumes-and-issues/45-4>

[Reviewed earlier]

Journal of the Royal Society – Interface

January 2025 Volume 22 Issue 222

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

Journal of Travel Medicine

Volume 31, Issue 8, December 2024

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

Journal of Virology

Volume 98 Number 12 December 2024

<http://jvi.asm.org/content/current>

[Reviewed earlier]

The Lancet

Feb 01, 2025 Volume 405 Number 10476 p353-438

<https://www.thelancet.com/journals/lancet/issue/current>

Articles

[Suspected and confirmed mpox cases in DR Congo: a retrospective analysis of national epidemiological and laboratory surveillance data, 2010–23](#)

Eugene Bangwen, et al.

Summary

Background

DR Congo has the highest global burden of mpox, a disease caused by infection with the monkeypox virus. The incidence has risen since 1980, but recent analyses of epidemiological trends are lacking. We aimed to describe trends in suspected and confirmed mpox cases in DR Congo using epidemiological and laboratory mpox surveillance data collected from 2010 to 2023, and provide insights that can better inform the targeting and monitoring of control strategies.

Methods

We analysed aggregated national epidemiological surveillance data and individual-level laboratory data from 2010 to 2023. We calculated incidence based on suspected cases, case-fatality ratios, and percentage of laboratory-confirmed cases and assessed geospatial trends. Demographic and seasonal trends were investigated using generalised additive mixed models.

Findings

Between Jan 1, 2010, and Dec 31, 2023, a total of 60 967 suspected cases and 1798 suspected deaths from mpox were reported in DR Congo (case-fatality ratio 2·9%). The number of reporting provinces increased from 18 of 26 provinces in 2010 to 24 of 26 provinces in 2023. The annual incidence increased from 2·97 per 100 000 in 2010 to 11·46 per 100 000 in 2023. The highest incidence (46·38 per 100 000) and case-fatality ratio (6·0%) were observed in children younger than 5 years. Incidence was higher in rural compared with urban areas. PCR testing was performed for 7438 suspected cases (12·2%), with 4248 (57·1%) of 7438 samples testing positive. Median age of confirmed cases (13·0 years [IQR 6·0–25·0]) remained stable, although the 95th percentile of age increased over time.

Interpretation

The incidence and geographical distribution of suspected mpox cases have increased substantially since 2010. Improvements in surveillance and decentralised testing are essential to monitor mpox trends and direct interventions effectively, to address the public health emergency declarations issued in August, 2024

The Lancet Child & Adolescent Health

Jan 2025 Volume 9 Number 1 p1-76

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

Lancet Digital Health

Jan 2025 Volume 7 Number 1 e1-e102

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

Lancet Global Health

Jan 2025 Volume 13 Number 1 e1-e171

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

Lancet Infectious Diseases

Jan 2025 Volume 25 Number 1 p1-134, e1-e59

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

Lancet Public Health

Jan 2025 Volume 10 Number 1 e1-e70

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

Lancet Respiratory Medicine

Jan 2025 Volume 13 Number 1 p1-100, e1-e8

<https://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

Maternal and Child Health Journal

Volume 28, Issue 12 December 2024

<https://link.springer.com/journal/10995/volumes-and-issues/28-12>

[Reviewed earlier]

Medical Decision Making (MDM)

Volume 45 Issue 1, January 2025

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy

Volume 102, Issue 4 Pages: 823-1031 December 2024

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

Molecular Therapy

Jan 08, 2025 Volume 33 Issue 1 p1-422

<https://www.cell.com/molecular-therapy/current>

[Reviewed earlier]

Nature

Volume 637 Issue 8048, 30 January 2025

<https://www.nature.com/nature/volumes/637/issues/8048>

Perspective 20 Nov 2024

[The Human Cell Atlas from a cell census to a unified foundation model](#)

This Perspective explores five ways in which cell atlases are revealing valuable biological insights, and how they are poised to provide considerable benefits in the coming years.

Jennifer E. Rood, Samantha Wynne, Aviv Regev

Nature Biotechnology

Volume 43 Issue 1, January 2025

<https://www.nature.com/nbt/volumes/43/issues/1>

[Reviewed earlier]

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 01 Feb 2025)

[Reviewed earlier]

Nature Genetics

Volume 57 Issue 1, January 2025

<https://www.nature.com/ng/volumes/57/issues/1>

[Reviewed earlier]

Nature Human Behaviour

Volume 9 Issue 1, January 2025

<https://www.nature.com/nathumbehav/volumes/9/issues/1>

[New issue; No digest content identified]

Nature Medicine

Volume 31 Issue 1, January 2025

<https://www.nature.com/nm/volumes/31/issues/1>

World View 17 Jan 2025

How patient advocates influence health policy

Scientists can learn the power of storytelling and coalition-building from patient advocates.

Elizabeth Kasimu Mutunga

Review Article 20 Jan 2025

Artificial intelligence in drug development

This Review explores the state-of-the-art applications of artificial intelligence in small-molecule drug development, from target identification and drug synthesis up to clinical trial design and conduct.

Kang Zhang, Xin Yang, Shengyong Yang

Abstract

Drug development is a complex and time-consuming endeavor that traditionally relies on the experience of drug developers and trial-and-error experimentation. The advent of artificial intelligence (AI) technologies, particularly emerging large language models and generative AI, is poised to redefine this paradigm. The integration of AI-driven methodologies into the drug development pipeline has already heralded subtle yet meaningful enhancements in both the efficiency and effectiveness of this process. Here we present an overview of recent advancements in AI applications across the entire drug development workflow, encompassing the identification of disease targets, drug discovery, preclinical and clinical studies, and post-market surveillance. Lastly, we critically examine the prevailing challenges to highlight promising future research directions in AI-augmented drug development.

Article 02 Jan 2025

An evaluation framework for clinical use of large language models in patient interaction tasks

By simulating realistic doctor–patient conversations, a framework can be applied to large language models to investigate shortcomings and bias in patient interactions, providing insight before actual clinical deployment.

Shreya Johri, Jaehwan Jeong, Pranav Rajpurkar

Global genomic surveillance of monkeypox virus

An analysis of all available mpox virus sequences, including 10,670 sequences from 65 countries collected between 1958 and 2024, unveils the circulation pattern and spatiotemporal dynamics underlying the spread of the different viral clades.

James R. Otieno, Christopher Ruis, Lorenzo Subissi

Nature Reviews Drug Discovery

Volume 24 Issue 1, January 2025

<https://www.nature.com/nrd/volumes/24/issues/1>

[Reviewed earlier]

Nature Reviews Genetics

Volume 26 Issue 1, January 2025
<https://www.nature.com/nrg/volumes/26/issues/1>
[Reviewed earlier]

Nature Reviews Immunology

Volume 25 Issue 1, January 2025
<https://www.nature.com/nri/volumes/25/issues/1>
[New issue; No digest content identified]

New England Journal of Medicine

Volume 392 No. 5 January 30, 2025
<https://www.nejm.org/toc/nejm/medical-journal>
Editorial

A Milestone for Gene-Editing Therapies

Author: Kiran Musunuru, M.D., Ph.D.

Abstract

Are gene-editing therapies actually helping patients? Although there has been considerable excitement about the prospect of directly administering gene-editing therapy that is based on clustered regularly interspaced short palindromic repeats (CRISPR)–CRISPR-associated protein 9 (Cas9) into the bodies of patients to treat diseases,¹ we have only recently begun to see signs of success in clinical settings...

NEJM Evidence

Volume 4 No. 2 February 2025
<https://evidence.nejm.org/toc/evid/current>
NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.
[New issue; No digest content identified]

npj Vaccines

<https://www.nature.com/npjvaccines/>
[Accessed 01 Feb 2025]
[No new digest content identified]

Pediatrics

Volume 155, Issue 1 1 January 2025
<https://publications.aap.org/pediatrics/issue/155/1>
[Reviewed earlier]

PharmacoEconomics

Volume 43, Issue 1 January 2025
<https://link.springer.com/journal/40273/volumes-and-issues/43-1>
[Reviewed earlier]

PLoS Biology

<https://journals.plos.org/plosbiology/>

(Accessed 01 Feb 2025)
[No new digest content identified]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 01 Feb 2025)
[No new digest content identified]

PLoS Global Public Health

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60

(Accessed 01 Feb 2025)

[The Neglected Tropical Disease Non-Governmental Organization Network: The role of a global health network in an evolving global health landscape](#)

Girija Sankar, Arielle Dolegui, Jemish Acharya

Research Article | published 31 Jan 2025 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0004078>

[A framework for managing infectious diseases in rural areas in low- and middle-income countries in the face of climate change—East Africa as a case study](#)

Katherine E. L. Worsley-Tonks, Shaleen Angwenyi, Colin Carlson, Guéladio Cissé, Sharon L. Deem, Adam W. Ferguson, Eric M. Fèvre, Esther G. Kimaro, David W. Kimiti, Dino J. Martins, Lutz Merbold, Anne Mottet, Suzan Murray, Mathew Muturi, Teddie M. Potter, Shailendra Prasad, Hannah Wild, James M. Hassell

Review | published 30 Jan 2025 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0003892>

PLoS Medicine

<https://journals.plos.org/plosmedicine/>

(Accessed 01 Feb 2025)
[No new digest content identified]

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 01 Feb 2025)
[No new digest content identified]

PLoS One

<http://www.plosone.org/>

[Accessed 01 Feb 2025]

[Navigating vaccination in pregnancy: Qualitative study in 21 ethnically diverse pregnant women](#)

Mohammad S. Razai, Michael Ussher, Lucy Goldsmith, Sally Hargreaves, Pippa Oakeshott

Research Article | published 31 Jan 2025 PLOS ONE

<https://doi.org/10.1371/journal.pone.0310823>

PLoS Pathogens

<http://journals.plos.org/plospathogens/>

[Accessed 01 Feb 2025]

[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

February 4, 2025 | vol. 122 | no. 5

<https://www.pnas.org/toc/pnas/122/5>

Perspective January 27, 2025

[How should the advancement of large language models affect the practice of science?](#)

Large language models (LLMs) are being increasingly incorporated into scientific workflows. However, we have yet to fully grasp the implications of this integration. How should the advancement of large language models affect the practice of science? For ...

Marcel Binz, et al.

PNAS Nexus

Volume 4, Issue 1, January 2025

<https://academic.oup.com/pnasnexus/issue/4/1>

Biophysics and Computational Biology

[Modeling of randomized hepatitis C vaccine trials: Bridging the gap between controlled human infection models and real-world testing](#)

Mary-Ellen Mackesy-Amity and others

Demography

[Indirect effects of the COVID-19 pandemic: A cause-of-death analysis of life expectancy changes in 24 countries, 2015 to 2022](#)

Antonino Polizzi and others

Prehospital & Disaster Medicine

Volume 39 - Issue 4 - August 2024

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

Preventive Medicine

Volume 191 February 2025

<https://www.sciencedirect.com/journal/preventive-medicine/vol/191/suppl/C>

[New issue; No digest content identified]

Proceedings of the Royal Society B

January 2025 Volume 292 Issue 2039

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]

Public Health

Volume 238 Pages 1-316 (January 2025)

<https://www.sciencedirect.com/journal/public-health/vol/238/suppl/C>

Research article Open access

Impact of COVID-19 pandemic on vaccine hesitancy and sentiment changes: A survey of healthcare workers in 12 countries

Andrea Parisi, Luca Regazzi, Emma Sophie Spanaus, Angelica Valz Gris, ... Marta Lomazzi
Pages 188-196

Research article Open access

Unlocking the key to HPV prevention: Exploring factors influencing HPV vaccination decisions among young people and their parents

Hüsna Sarıca Çevik, Ana Amariutei, Anastasiia Mazur, Gülsen Ceyhun Peker, ... Mehmet Ungan
Pages 214-220

Research article Open access

COVID-19 vaccine hesitancy among caregivers of children under five years old in a pediatric emergency department

Lauren Van Woy, Tamara Casas, Ashish Shah, Elizabeth Chang
Pages 266-273

Public Health Ethics

Volume 17, Issue 3, November 2024

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

Public Health Genomics

2024, Vol. 27, No. 1

<https://karger.com/phg/issue/27/1>

[Reviewed earlier]

Public Health Reports

Volume 139 Issue 6, November/December 2024

<https://journals.sagepub.com/toc/phrg/139/6>

[Reviewed earlier]

Qualitative Health Research

Volume 35 Issue 1, January 2025

<https://journals.sagepub.com/toc/QHR/current>

[Reviewed earlier]

Research Ethics

Volume 21 Issue 1, January 2025

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 01 Feb 2025]

[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

Latest Articles

[No new digest content identified]

Risk Analysis

Volume 45, Issue 1 Pages: 1-263 January 2025

<https://onlinelibrary.wiley.com/toc/15396924/current>

[New issue; No digest content identified]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 01 Feb 2025]

[No new digest content identified]

Royal Society Open Science

January 2025 Volume 12 Issue 1

<https://royalsocietypublishing.org/toc/rsos/current>

[New issue; No digest content identified]

Science

Volume 387| Issue 6733| 31 Jan 2025

<https://www.science.org/toc/science/current>

Policy Forum

Taking responsibility: Asilomar and its legacy

BY J. Benjamin Hurlbut

30 Jan 2025: 468-472

A reappraisal of the constitutional position of science in American democracy is needed

... Even efforts to foster deliberation in the tradition of Asilomar like the three international summits on human genome editing have taken steps to broaden deliberation. But displacing old habits and building capacity that fosters new and better ones takes time, practice, and often-uncomfortable self-critique ([15](#)).

This spring, the Global Observatory on Genome Editing (of which I am a co-director), itself an experiment in deliberation, will host a summit that, contra Asilomar, radically expands the range of questions and perspectives that societies should take into account. It will begin with diverse understandings of the meaning of being human—cultural, legal, religious, and scientific—and explore their implications for projects in biotechnology. The hope is to start laying the groundwork for a genuinely global social compact that contends with the distribution of benefits and harms and the asymmetries in power and resources that order global science and technology. It will eschew the drive for scientific consensus in favor of cosmopolitan deliberation that affirms disagreement and aspires to mutual understanding and humility over artificial univocality.

That projected meeting is but one small step on a winding pathway. Traveling it requires abandoning Asilomar's ideology of linear progress. We must ask anew what experiments should be done—not merely in the enclaves of science and technology but in the laboratories of democracy worldwide—such

that our scientific and technological projects can more truly align with democratically articulated imaginations of the good. Let us celebrate this 50th anniversary of Asilomar by relegating it to the past where it belongs and embracing the hard task of democratic renewal that lies before us.

Science and Engineering Ethics

Volume 31, Issue 1 February 2025

<https://link.springer.com/journal/11948/volumes-and-issues/31-1>

[Reviewed earlier]

Science Translational Medicine

Volume 17| Issue 783| 29 Jan 2025

<https://www.science.org/toc/stm/current>

Research Articles

Prior vaccination prevents overactivation of innate immune responses during COVID-19 breakthrough infection

BY Leslie Chan, et al.

29 Jan 2025

SARS-CoV-2 breakthrough infections in previously vaccinated individuals are characterized by reduced activation of innate immune responses.

Scientific Reports

<https://www.nature.com/srep/articles?type=article>

[Accessed 01 Feb 2025]

[No new digest content identified]

Social Science & Medicine

Volume 364 January 2025

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/364/suppl/C>

[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 01 Feb 2025]

[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 45, Issue 6 December 2024

<https://link.springer.com/journal/11017/volumes-and-issues/45-6>

[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 63 January–February 2025

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/63/suppl/C>

[Reviewed earlier]

Tropical Medicine & International Health

Volume 30, Issue 1 Pages: i-iv, 1-69 January 2025

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

Vaccine

Volume 47 15 February 2025

<https://www.sciencedirect.com/journal/vaccine/vol/47/suppl/C>

Short communication Abstract only

Perspectives on vaccination among unvaccinated members of a Canadian indigenous population

Tasha Shields, K.D. King, Shelley Cripps, Sarah A. Edwards, ... Martin Cooke

Article 126665

Review article Open access

Post-exposure prophylaxis for the prevention of measles: A systematic review

Joshua Montroy, Cathy Yan, Faizan Khan, Nicole Forbes, ... Marina I. Salvadori

Article 126706

Review article Open access

A systematic review and meta-analysis of adverse events following measles-containing vaccines in infants less than 12 months of age

Dorthe Maria Vittrup, Salma Charabi, Andreas Jensen, Lone Graff Stensballe

Article 126687

Research article Open access

Danish parents' vaccination readiness is associated with their children's officially registered vaccination history

Ana Paula Santana, Bolette Søbørg, Stine Ulendorf Jacobsen, Ingo Zettler, Robert Böhm

Article 126693

Research article Open access

Immunogenicity of yellow fever vaccine co-administered with 13-valent pneumococcal conjugate vaccine in rural Gambia: A cluster-randomised trial

Isaac Osei, Jonas Schmidt-Chanasit, Paul V. Licciardi, Ousman Secka, ... Grant A. Mackenzie

Article 126712

Research article Abstract only

Navigating vaccine confidence: A mixed methods study investigating healthcare providers' perspectives across four non-EU European regions

Toni Claessens, Rachel L. Eagan, Greet Hendrickx, Pierre Van Damme, ... Emilie Karafillakis

Article 126694

Vaccines

<https://www.mdpi.com/journal/vaccines>

[Accessed 01 Feb 2025]

Open Access Review

Progress and Challenges in HIV-1 Vaccine Research: A Comprehensive Overview

by Alex C. Boomgarden and Chitra Upadhyay

Vaccines 2025, 13(2), 148; <https://doi.org/10.3390/vaccines13020148> - 31 Jan 2025

Abstract

The development of an effective HIV-1 vaccine remains a formidable challenge in biomedical research. Despite significant advancements in our understanding of HIV biology and pathogenesis, progress has been impeded by factors such as the virus's genetic diversity, high mutation rates, and its ability [...]

Open Access Article

[Exploring Parent-Driven Determinants of COVID-19 Vaccination in Indigenous Children: Insights from a National Survey](#)

by Abdallah Alami, Saily Dave, Marwa Ebrahim, Israa Zareef, Caren Uhlik and Julie Laroche

Vaccines 2025, 13(2), 132; <https://doi.org/10.3390/vaccines13020132> - 28 Jan 2025

Abstract

Background: Globally and in Canada, Indigenous populations have faced heightened vulnerability during pandemics, with historical inequities exacerbated by multigenerational colonial policies. This study aimed to identify parental factors influencing COVID-19 vaccination among Indigenous children in Canada. Methods: Data from a nationally representative, cross-sectional [...]

Open Access Article

[Understanding HPV Vaccine Initiation and Intention Among Central American Immigrant Parents in the United States: The Role of Vaccine Literacy and Healthcare Provider Recommendations](#)

by Doris Lucero, Virginia A. Moreno, Denisse Delgado, Axel Hernandez Nieto, Nachalie Rodriguez-Cruz, Qun Le and Ana Cristina Lindsay

Vaccines 2025, 13(2), 130; <https://doi.org/10.3390/vaccines13020130> - 27 Jan 2025

Abstract

Background/Objectives: The HPV vaccine is key to preventing HPV-related cancers, yet vaccination rates are low, particularly among immigrant and ethnic minority groups. This study explored factors influencing HPV vaccine initiation and intention among Central American immigrant parents in the U.S.

Value in Health

February 2025 Volume 28 Issue 2 p175-322

<https://www.valueinhealthjournal.com/current>

ISPOR Report

[Generative Artificial Intelligence for Health Technology Assessment: Opportunities, Challenges, and Policy Considerations: An ISPOR Working Group Report](#)

Rachael L. Fleurence, et al. on behalf of the ISPOR Working Group on Generative AI

Published online: November 10, 2024

p175-183

Themed Section: Rare Diseases: Economic Evaluation and Policy Considerations

[A Standardized Measurement and Valuation Scale of Genomic Utility for Policy Decisions: The GUV Scale](#)

Ilias Goranitis, et al.

Published online: December 24, 2024

p184-190 Open Access

Health Policy Analysis

[Financial Impacts of Paying for Gene Therapy for Sickle Cell Disease Under Alternative Pricing and Financing Mechanisms](#)

Anirban Basu

Published online: November 10, 2024

World Development

Volume 185 January 2025

<https://www.sciencedirect.com/journal/world-development/vol/184/suppl/C>

[Reviewed earlier]

.....
.....

Contents [click to move among sections]

:: [*Milestones, Perspectives*](#)

:: [*WHO*](#)

:: [*Organization Announcements*](#)

:: [*Journal Watch*](#)

:: [*Pre-Print Servers*](#)

.....
.....

Pre-Print Servers

arxiv

<https://arxiv.org/>

[Accessed 01 Feb 2025]

[Filters: Emerging Technologies; Neural and Evolutionary Computing; Computers and Society; Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology; General Economics]

arXiv:2501.17005 [pdf, other]

[Seasonal Influenza Vaccination Hesitancy and Digital Literacy: Evidence from the European countries](#)

[Martina Celidoni](#), [Nita Handastya](#), [Guglielmo Weber](#), [Nancy Zambon](#)

This study documents the relationship between computer skills/digital literacy and influenza vaccination take-up among older adults in Europe during and after the COVID-19 pandemic. Using data from the Survey of Health, Aging and Retirement in Europe, we find a positive partial association between influenza vaccination take-up and two indicators of computer skills/digital literacy, self-assessed pre-pandemic computer skills and having used a computer at work in any pre-pandemic job. We do not estimate significant behavioural changes for individuals with better computer skills that may have been driven by spillover effects from the pandemic experience.

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 01 Feb 2025]

[No new digest content identified]

medRxiv

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 01 Feb 2025]

[Filter: All articles]

[Pregnancy Reduces COVID-19 Vaccine Immunity Against Novel Variants](#)

Maclaine A Parish, Jaiprasath Sachithanandham, Lizeth Gutierrez, Han-Sol Park, Anna Yin, Katerina Roznik, Patrick Creisher, John S Lee, Laura A St Clair, Annie Werner, Susan Bersoff-Matcha, Catherine Pilgrim-Grayson, Lee Berhane, Hana Golding, Patrick Shea, Katherine Fenstermacher, Richard Eric Rothman, Irina Burd, Jeanne Sheffield, Andrea L Cox, Andrew Pekosz, Sabra Klein
medRxiv 2025.01.29.25321357; doi: <https://doi.org/10.1101/2025.01.29.25321357>

Modern approaches to predicting vaccine hesitancy: A scoping review

Keshav R. Gandhi, Sami Alahmadi, Rosie Hanneke, Alexander Gutfraind
medRxiv 2025.01.29.25321367; doi: <https://doi.org/10.1101/2025.01.29.25321367>

Addressing the challenges of estimating the target population in calculation of routine infant immunization coverage in Kenya

Christine Karanja-Chege, Ambrose Agweyu, Fred Were, Michael Boele van Hensbroek, William Ogallo
medRxiv 2025.01.30.25321415; doi: <https://doi.org/10.1101/2025.01.30.25321415>

A dynamic transmission model for assessing the impact of pneumococcal vaccination in the United States

Tufail M Malik, Kevin M Bakker, Rachel J Oidtman, Oluwaseun Sharomi, Giulio Meleleo, Robert B Nachbar, Elamin H Elbasha
medRxiv 2024.06.11.24308671; doi: <https://doi.org/10.1101/2024.06.11.24308671> Revision

Navigating the Multiverse: A Hitchhiker's Guide to Selecting Harmonisation Methods for Multimodal Biomedical Data

Murali Aadhitya Magateshvaren Saras, Mithun K. Mitra, Sonika Tyagi
medRxiv 2024.03.21.24304655; doi: <https://doi.org/10.1101/2024.03.21.24304655> Revision

The application of machine learning (ML) techniques in classification and prediction tasks has greatly advanced our comprehension of biological systems. There is a notable shift in the trend towards integration methods that specifically target the simultaneous analysis of multiple modes or types of data, showcasing superior results compared to individual analyses. Despite the availability of diverse ML architectures for researchers interested in embracing a multimodal approach, the current literature lacks a comprehensive taxonomy that includes the pros and cons of these methods to guide the entire process. Closing this gap is imperative, necessitating the creation of a robust framework. This framework should not only categorise the diverse ML architectures suitable for multimodal analysis but also offer insights into their respective advantages and limitations. Additionally, such a framework can act as a guide for selecting an appropriate workflow for multimodal analysis. This comprehensive taxonomy would furnish a clear guidance and aid in informed decision-making within the progressively intricate realm of biomedical and clinical data analysis, and is imperative for advancing personalised medicine.

Impact of Electronic Immunization Registries and Electronic Logistics Management Information Systems in four Low-and Middle-Income Countries: Guinea, Honduras, Rwanda, and Tanzania

C Mantel, C Hugo, C Federici, N Sano, S Camara, E Rodriguez, L Castillo, J Condo, P Irakiza, I Sabi, E Nyanda, W Olomi, M Cavazza, V Mangiaterra, M Verykiou, E Ferenchick, A Torbica, T Cherian, S Malvolti
medRxiv 2025.01.27.25321171; doi: <https://doi.org/10.1101/2025.01.27.25321171>

Patterns of reporting of influenza and pertussis vaccination during pregnancy to the Australian Immunisation Register, 2022

Nicole Sonneveld, Elizabeth Wilson, Sonya Ennis, Jocelyne McRae, Kristine Macartney, Bette Liu
medRxiv 2025.01.23.25320512; doi: <https://doi.org/10.1101/2025.01.23.25320512>

AI regulation in healthcare around the world: what is the status quo?

Felix Busch, Raym Geis, Yuan-Cheng Wang, Jakob Nikolas Kather, Noor Al Khor, Marcus R Makowski, Israel K Kolawole, Daniel Truhn, Warren Clements, Stephen Gilbert, Lisa C Adams, Esteban Ortiz-Prado, Keno K Bresse

medRxiv 2025.01.25.25321061; doi: <https://doi.org/10.1101/2025.01.25.25321061>

Summary

The rapid adoption of artificial intelligence (AI) raises challenges related to ethics, safety, equity, and governance that require robust regulatory frameworks. In most jurisdictions, AI-driven medical devices are already covered by existing medical device frameworks, although new AI-specific legislation may be required to address the challenges posed by recent advancements. This expert review focuses on frameworks and legislation explicitly tailored to AI, synthesizing research literature, government and intergovernmental framework programs, and online media coverage to provide an up-to-date assessment of global AI-specific regulation or strategies in healthcare as of December 2024. Our findings show that only 15.2% (n=30/197) of countries or territories have enacted legally binding AI-specific legislation, including the 27 member states of the European Union (EU) following the adoption of the EU AI Act. A further 9.1% (n=18/197) have drafted legislation, and 28.4% (n=56/197) have issued non-binding guidelines. Notably, 47.2% (n=93/197) of countries or territories do not have an AI-specific framework or legislation in place. Furthermore, our results highlight disparities between the Global North and South, with 60.3% (n=82/136) of Global South countries or territories lacking frameworks or legislation, compared to 18% (n=11/61) in the Global North. In conclusion, our work provides an overview of the status quo of AI regulation around the world, highlights disparities in the adoption of frameworks and legislation, and calls for the need for intergovernmental and regional cooperation.

OSF Pre-prints

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

[Provider Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints]

Selected Research

Preprint

Pay-it-forward to Increase the Uptake of Pneumococcal Vaccine among Older Adults: A Two-arm Randomized Controlled Trial in China

Ting Huang, Shuiming Chen, Joseph Tucker, Yanxiao Gao, Xianyan Tang, and 16 more

Date created: 2025-01-24 Date modified: 2025-01-31

Abstract

Background: Pneumococcal vaccination has a mortality benefit among older adults, but many do not receive it. This pilot study aims to evaluate the effectiveness of a pay-it-forward intervention on pneumococcal vaccine uptake among older adults in Guangxi Province, China.

Methods: From January to September 2024, a two-arm parallel randomized controlled trial was conducted in four community health centers in Nanning City, Guangxi Province, China. We recruited older adults aged 60 or older who met the medical criteria for pneumococcal vaccine in the CHSCs. We used block randomization, and blocks of four older adults were assigned (1:1) to a pay-it-forward arm and a standard-of-care arm. The primary outcome was pneumococcal vaccination 1 month after the intervention. Secondary outcomes included the influenza vaccination uptake, the cost-effectiveness of the pay-it-forward intervention, vaccine confidence, and peer vaccine referral.

Results: 220 eligible older adults participated in the study, and 214 followed up at four weeks. Most participants were female (57.5%), 60-70 years old (59.3%), married (81.8%), had a high school education or less (73.8%), and had chronic diseases (69.6%). In the pay-it-forward arm, 70.2% (73/104) of participants received the PPSV-23 vaccine, and 31.7% (33/104) received the influenza vaccine, compared to 13.6% (15/110) and 17.3% (19/110), respectively, in the standard-of-care arm. Participants in the pay-it-forward group were more likely to receive the pneumococcal vaccine and influenza vaccine than those in the standard-of-care arm, with an adjusted odds ratio (aOR) of

19.4(95% CI: 8.88–46.6) and 2.43 (95% CI: 1.19–4.94), respectively. In addition, the participants in the pay-it-forward group exhibited higher confidence in vaccine safety (3.90, 95% CI: 1.63–10.33), vaccine administration (3.18, 95% CI: 1.00–11.97), vaccine importance (5.01, 95% CI: 2.01–14.08), and vaccine effectiveness (9.24, 95% CI: 2.98–36.84) than those in the standard-of-care group. 51.9%(54/104) participants contributed to donate for the next pay-it-forward recipients. The pay-it-forward group had a higher peer vaccine referral rate (41.4% vs. 58.6%, $p=0.66$) and had a lower economic cost per person vaccinated (\$268.49 vs. \$103.10) compared to the standard-of-care arm.

Conclusion: These findings suggest that the pay-it-forward intervention Can increase pneumococcal and influenza vaccine uptake rates. This highlights the need for implementing pay-it-forward interventions and donation strategies to improve the uptake of necessary vaccinations.
Trial registration: Chinese Clinical Trial Registry ChiCTR2400079410.

Wellcome Open Research

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 01 Feb 2025]

[No new digest content identified]

* * * *

Think Tanks

Brookings [to 01 Feb 2025]

<http://www.brookings.edu/>

Reports, Events

No new digest content identified.

Center for Global Development [to 01 Feb 2025]

<https://www.cgdev.org/>

All Research

WORKING PAPERS

Costing Antimicrobial Resistance Interventions

Tim Laurence and Anthony McDonnell

January 29, 2025

This study estimates the costs of four key interventions to mitigate antimicrobial resistance globally by 2050. These interventions include improving access to water, sanitation, and hygiene, enhancing childhood vaccination, developing new antibiotics, and increasing access to healthcare and existin...

WORKING PAPERS

The Global Direct Inpatient Cost of Antimicrobial Resistance: A Modelling Study

Tim Laurence et al.

January 29, 2025

This study estimates the global inpatient healthcare costs attributable to antimicrobial resistance (AMR) and projects future expenditures across different scenarios. It finds that AMR accounts for 25.4 million hospital admissions annually, resulting in \$66.4 billion in excess healthcare costs, with...

WORKING PAPERS

Modelling the Global Economic Impact of Antimicrobial Resistance in Humans

Amanda Countryman and Anthony McDonnell

January 29, 2025

Antimicrobial resistance (AMR) poses a major global challenge, affecting both human health and economies. This research models the potential impacts of AMR on global GDP and various sectors, showing that while better treatment and combined interventions can boost economic growth, accelerated resista...

Chatham House [to 01 Feb 2025]

<https://www.chathamhouse.org/>

Selected Analysis, Comment, Events

No new digest content identified.

Council on Foreign Relations [to 01 Feb 2025]

<https://www.cfr.org/media/news-releases>

New Releases [Selected]

No new digest content identified.

CSIS [to 01 Feb 2025]

<https://www.csis.org/>

Reports [Selected]

No new digest content identified.

Kaiser Family Foundation [to 01 Feb 2025]

https://www.kff.org/search/?post_type=press-release

Newsroom

[Poll: Trust in Public Health Agencies and Vaccines Falls Amid Republican Skepticism](#)

January 28, 2025 News Release

As President Trump begins his second term, the public's trust in health information from key health agencies has fallen over the past 18 months, continuing a decline that began during the COVID-19 pandemic, finds the new KFF Tracking Poll on Health Information and Trust. Just over half (53%) of the...

McKinsey Global Institute [to 01 Feb 2025]

<https://www.mckinsey.com/mgi/overview>

Latest Research

No new digest content identified.

ODI [Overseas Development Institute] [to 01 Feb 2025]

<https://odi.org/en/publications/>

Publications [Selected]

No new digest content identified.

Pew Research Center [to 01 Feb 2025]

<https://www.pewresearch.org/>

Latest Publications [Selected]

short reads Jan 29, 2025

[4 facts about Americans' views of the World Health Organization](#)

Nearly six-in-ten Americans (58%) say the U.S. benefits from its membership in the World Health Organization.

Report Jan 28, 2025

Comparing Levels of Religious Nationalism Around the World

We asked people in three dozen countries how they see religion’s role in society, government and national identity.

Rand [to 01 Feb 2025]

<https://www.rand.org/pubs.html>

Published Research [Selected]

Research Jan 30, 2025

Consent and Assent in Pediatric Research

D. Micah Hester, Skye A. Miner

Research - Posted on rand.org Jan 30, 2025 Published in: Pediatric Clinics of North America, Volume 71, Issue 1, pages 83-92 (February 2024). DOI: 10.1016/j.pcl.2023.08.003

The process of soliciting a minor's assent has moral import, even if it is not always required by the current regulations. Ethically, the process provides for the child's opinion to be heard, for respecting their developing capacity and involving the child as a participant in research.

Research Jan 28, 2025

Mitigating Risks at the Intersection of Artificial Intelligence and Chemical and Biological Weapons

The authors assess the risks posed by artificial intelligence (AI) to generate or exacerbate chemical and biological threats and how such misuse of AI could be mitigated or prevented.

Urban Institute [to 01 Feb 2025]

<https://www.urban.org/publications>

New Research Publications - Selected

Summary

What Would Reducing the Federal Workforce Look Like for America?

January 30, 2025

World Economic Forum [to 01 Feb 2025]

<https://agenda.weforum.org/press/>

Media [Selected]

No new digest content identified.

* * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy ([CVEP](#)) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2025. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

*	*	*	*
*	*	*	*